



Consumer and  
Corporate Affairs

Patent Office

**Certification**

RECEIVED

MAR 20 1993

GROUP 150

Consommation et  
Corporations

Bureau des brevets

**Certification**

*Part 8  
#9*


The documents attached hereto and identified below are hereby certified to be true copies of the papers on file in the Patent Office of Canada.

Il est certifié par les présentes que les documents ci-joints, dont la liste figure ci-dessous, sont des copies authentiques des documents déposés au Bureau des brevets du Canada.

Specification and Drawings, as originally filed, with Application for Patent Serial No. 2,061,566, on February 20, 1992, by **Norpharmo Inc.**, assignee of Rudolf E. Falk and Samuel S. Asculai, for "Treatment of Disease Employing Hyaluronic Acid and Nsaids".

In testimony whereof I have set my hand and caused the Seal of the Patent Office to be hereunto affixed at Hull, Canada, on 92/10/20

En foi de quoi j'ai signé les présentes et y ai fait apposer le sceau du Bureau des brevets à Hull, Canada, le



**Canada**

*[Signature]*  
Attesting Officer—Certificateur



Concommission  
et Corporations Canada

Consumer and  
Corporate Affairs Canada

Bureau des brevets

Patent Office

Ottawa, Canada  
K1A 6C9

(21)	(A1)	2,061,566
(22)		1992/02/20
(43)		1993/08/21

(51) INTL.CL.<sup>5</sup> A61K-047/36

(19) (CA) APPLICATION FOR CANADIAN PATENT (12)

(54) Treatment of Disease Employing Hyaluronic Acid and  
Nsaids

(72) Falk, Rudolf E. - Canada ;  
Asculai, Samuel S. - Canada ;

(73) Norpharmco Inc. - Canada ;

(57) 25 Claims

Notice: The specification contained herein as filed

**Canada**

ABSTRACT

2061566

A topically applied transdermally penetrating systemic independent acting pharmaceutical combination and formulation for the treatment of a disease or condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts (condyloma acuminata) cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women, comprising, together with pharmaceutical excipients suitable for topical application, a therapeutically effective non-toxic amount of a drug which inhibits prostaglandin synthesis administered with, or carried in, an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid (preferably hyaluronic acid and salts thereof) sufficient to facilitate the drug's penetration through the skin and tissue (including any scar tissue) at the site requiring treatment, to block prostaglandin synthesis.

TITLE OF INVENTION

2061566

TREATMENT OF DISEASE AND CONDITIONS

FIELD OF INVENTION

This invention relates to the treatment of disease and  
5 conditions of the skin and exposed tissue. In some embodiments  
this invention finds application to the treatment of a disease  
or condition of the skin and exposed tissue including (basal  
cell carcinoma, squamous cell tumours, metastatic cancer of the  
breast to the skin, primary and metastatic, melanoma in the  
10 skin, genital warts (condyloma acuminata), cervical cancer, HPV  
(Human Papilloma Virus) including HPV (Human Papilloma Virus) on  
the cervix, psoriasis (both plaque-type psoriasis and nail bed  
psoriasis), corns on the feet, and actinic keratoses lesions,  
"liver" spots, fungal lesions, and other such types of lesions,  
15 and hair loss on the head of pregnant women.)

This invention also relates to formulations suitable  
for use in such treatments, the use of such formulations in such  
treatments, methods of such treatment, and the delivery of drugs  
for such treatments.

20 BACKGROUND OF THE INVENTION

Basal cell carcinoma is presently treated by surgery.  
Each lesion, together with all surrounding and underlying tissue  
(dermis, epidermis, and subdermis), is cut out. In some  
instances, surgery, while necessary for the patient's welfare,  
25 may put the patient at risk in some other respect (for example,  
a lesion on a patient's temple whose removal (resection) may  
jeopardize the patient's health). Squamous cell tumours are also  
treated the same way as are other forms of cancer in the skin  
and exposed tissue. Furthermore, other conditions and diseases  
30 of the skin and exposed tissue are treated the same way or in

ways that cause discomfort to the patient, for example melanoma, genital warts, cervical cancer, HPV (Human Papilloma Virus).

Actinic keratoses lesion is dealt with similarly. Additionally, liquid nitrogen has been used to remove the  
5 lesion.

These diseases and conditions are usually found in the epidermis (at least for the most part extending into the dermis and through Stratum Corneum).

Hyaluronic acid is a naturally occurring  
10 glycosaminoglycan. Its molecular weight may vary from 50,000 dalton upwards, and it forms highly viscous solutions. As regards the actual molecular weight of hyaluronic acid in natural biological contexts, this is still a matter of much uncertainty; when the molecular weight of hyaluronic acid is to  
15 be determined, different values are obtained depending on the assay method employed, and on the source, the isolation method etc. The acid occurs in animal tissue, e.g. spinal fluid, ocular fluid, synovial fluid, cockscombs, skin, and also in some streptococci. Various grades of hyaluronic acid have been  
20 obtained. A preparation with an allegedly high degree of purity and alleged to be entirely free from side effects, is a non-inflammatory form described in U.S. Patent No.4,141,973; this preparation is said to have a molecular weight exceeding 750,000 dalton, preferably exceeding 1,200,000 dalton and is suggested  
25 for therapeutic use in various articular conditions.

United States Patent 4,801,619 relates to hyaluronic acid, having a molecular weight of about  $3 \times 10^6$  dalton or more, administered intra-articularly which is prone to decrease the

proteoglycan content of synovial fluid to almost normal levels. According to this patent, this indicates a positive effect on the proteoglycan metabolism of a joint. According to the patent, this is applicable both to inflammatory conditions and

5 to degeneration caused by treatment with symptomatics, such as corticosteroid preparations. It is thus clear that a sufficiently high molecular weight of the hyaluronic acid is alleged to counteract side effects that might be caused by corticosteroids or other symptomatics producing similar effects.

10 When corticosteroids are applied, the amount of hyaluronic acid in the synovial cavity will, according to the patent, increase substantially and, according to the inventors, their hyaluronic acid preparations have a very positive effect on such clinical symptoms as pain, swelling, and lameness.

15 The patent states that the objectives of the invention are attained by intra-articular administration of an effective amount of hyaluronic acid with a mean molecular weight exceeding  $3 \times 10^6$  dalton, preferably exceeding  $4 \times 10^6$  dalton; usually the molecular weight will not exceed  $7 \times 10^6$  dalton. The dosage of  
20 hyaluronic acid administered is stated to be preferably within the range of 5mg-80mg. The amount of solution given at each administration is generally less than 60 ml, e.g. less than 20 ml. of an aqueous solution of the acid or its salt. It is convenient to administer the acid dissolved in water (<2% w/w,  
25 buffered to physiological pH), for instance in the form of a water-soluble sodium salt. The exact amount will depend on the particular joint to be treated.

The Merck Index Specifies that Hyaluronic Acid has a

Molecular Weight within the range of 50,000 to  $8 \times 10^6$  depending on source, methods of preparation, and methods of determination. The Merck Publication teaches hyaluronic acid as a surgical aid (ophthalmological).

5           United States Patent 4,808,576 purports to teach that hyaluronic acid, an agent well known for reducing the sequelae of trauma in mammalian joint tissue when applied directly to the traumatized tissue, will be carried to such traumatized tissue by the mammal's natural processes if applied at a site remote  
10 from the traumatized tissue. Thus, hyaluronic acid in any therapeutically acceptable form can, according to the Patent, be administered by the typical remote routes including intravenous, intramuscular, subcutaneous, and topical.

          This, the patent alleges, makes the utilization of  
15 hyaluronic acid much more convenient and attractive. For instance, the treatment of arthritis in horse or human joints with hyaluronic acid, according to the patent, no longer requires more difficult intra-articular injections.

          United States Patent 4,725,585 relates to a method of  
20 enhancing or regulating the host defence of a mammal, said method comprising administering to a mammal a therapeutically effective amount of hyaluronic acid.

          At column 1, lines 43 - 46, the patent provides that the invention was based on the unexpected discovery that  
25 administration of hyaluronic acid to mammals results in a considerable increase in the defence.

          The hyaluronic acid employed in the patent was Healon provided by Pharmacia AB, Uppsala, Sweden (Pharmacia AB is also

entitled to the benefit of United States Patent 4,141,973). The patent provides at column 4, line 19 that because a patient's infections had been hard to treat, instead of just hyaluronic acid being administered to the patient to increase the patient's  
5 defence, the patient was given hyaluronic acid and an antibiotic. While the patent states that the antibiotic was given in combination with hyaluronic acid, in fact because the hyaluronic acid was administered subcutaneously and because the patient was a heart patient, one skilled in the art would  
10 understand that any antibiotic administered, while possibly administered simultaneously was definitely administered separately intravenously (probably) or intramuscularly (less probably). Thus, (most probably) the hyaluronic acid administered, according to the teachings of this patent, was  
15 administered in order to prevent possible development of infections (increase the host's defence) and not for any other reason.

United States Patent 4,636,524 discloses cross-linked gels of hyaluronic acid, alone and mixed with other hydrophilic  
20 polymers and containing various substances or covalently bonded low molecular weight substances and processes for preparing them. These products are alleged to be useful in numerous applications including cosmetic formulations and as drug delivery systems.

25 The patent further states that as hyaluronic acid is known to be a biologically tolerable polymer in the sense that it does not cause any immune or other kind of response when introduced into a human body, the cross-linked hyaluronic acid



gels can be used for various medical applications. The cross-linked gels modified with other polymers or low molecular weight substances, it is alleged, can be used as drug delivery devices. For example, the inventors are alleged to have found that  
5 heparin introduced in a cross-linked hyaluronic acid gel retained its antithrombogenic activity.

The inventors also allege that they have also found that cross-linked gels of hyaluronic acid can slow down the release of a low molecular weight substance dispersed therein  
10 but not covalently attached to the gel macromolecular matrix.

Unites States Patent 4,736,024 purports to teach new medicaments for topical use containing:

- (i) an active pharmacological substance or a mixture  
of pharmacological substances, either active or  
15 suitable for topical administration and
- (ii) a topical vehicle which comprises hyaluronic acid or a molecular fraction of hyaluronic acid or a salt of the same with an alkaline metal, an alkaline earth metal, magnesium, aluminium, ammonium, or a pharmacological substance optionally  
20 together with additional conventional excipients for pharmaceutical preparations for topical use.

Applicants are also aware of published Japanese Patent Document 61000017, dated 86/01/06, whose English abstract of disclosure states that the Japanese Patent Document relates to  
25 the use of hyaluronic acid or cross-linked hyaluronic acid or their salts as the active ingredient for inhibiting carcinoma metastasis.

According to the purported abstract of the patent,

more than 1.0% of hyaluronic acid is dissolved in alkaline aq. soln. and pref. more than 50% of H<sub>2</sub>O sol. org. solvent. eq. alcohol, acetone, dioxane, against total soln. is added. Preferably the pH is 12-14. Then multifunctional epoxy cpd. is  
5 added and reacted at 10-60 deg. C, pref. at 20-40- deg. C for 24 hrs. Cross-linking ratio of crosslinked hyaluronic acid or its salt is regulated by changing mol ratio of hyaluronic acid or its salt and multifunctional epoxy cpd.. Pref. hyaluronic acid used has intrinsic viscosity 0.2-30, m.w. 4000-2000000. The  
10 hyaluronic acid is allegedly used in several dosage forms. Clinical dose for adult is alleged to be normally, as hyaluronic acid or cross-linked hyaluronic acid, 25mg-5 g/day (p.o.) and 10 mg-2.5 g/l dose (inj). The abstract alleges that the advantage is that the hyaluronic acid has no side effects as may other  
15 anti-cancer drugs and has an analgesic and a tissue restoration effect.

European Patent Application 0295092 purports to teach a vehicle together with fragments of hyaluronic acid for delivering of the fragments of hyaluronic acid into the skin to  
20 reach the dermal layer of the skin to increase the development of blood vessels for stimulating hair growth or regrowth. The preferred fragments of hyaluronic acid are polysaccharides containing from 7 to 25 monosaccharide units. The patent provides that it is apparent that the larger the fragments of  
25 hyaluronic acid, the greater the difficulty there is in delivering the fragments to the dermal layer of the skin, unless there is also present in the composition a means for enhancing the activity of said fragments.

The combination may thus include a means for enhancing the activity of the fragments of hyaluronic acid, especially to improve their penetration through the skin following topical application. Some activity enhancers, it is alleged, also  
5 function as vehicles for the fragments of the hyaluronic acid.

Some activity enhancers are also alleged to possess the ability to stimulate or increase hair growth. Minoxidil is asserted among others to be such an activity enhancer. Thus both the fragments of hyaluronic acid and minoxidil are alleged  
10 to stimulate hair growth both delivered by a vehicle.

European Patent Application 0179442 asserts that where free radicals are formed in considerable quantities, hyaluronic acid is broken down or degraded before the hyaluronic acid has given the desired effect.

15 Canadian Letters Patent 1,240,929 teaches the combination of chondroitin sulfate compound and a hyaluronate to protect both human and animal cell layers and tissue subject to exposure to trauma.

European Patent Application 0208623 purports to teach  
20 hyaluronic acid as "une augmentation de l'activité de certaines proteases". It also purports to teach the use of hyaluronic acid for treating connective tissue diseases, including malignant tumours and cardiovascular disorders.

European Patent Application 270317 purports to teach  
25 the combination of an antiviral agent lacking inhibitory action and a compound [for example, hyaluronic acid] possessing cell fusion inhibitory activity and/or virus-adsorption inhibitory activity for treating disease carried by a virus.

United States Patent 4,840,941 purports to teach the use of an effective amount of hyaluronic acid as the active agent for the treatment of retroviruses in association with a pharmaceutically acceptable carrier, diluent, or excipient.

5           United States Patent 4,851,521 and European Patent Application 0265116 both describe hyaluronic acid fractions, the making thereof and cross-linked esters of hyaluronic. United States Patent 4,851,521 describes esters of hyaluronic acid incorporated into pharmaceutical preparations as the active  
10 ingredient and as vehicles for ophthalmological medicines for topical use (See column 11, lines 35 to 42; and column 12, lines 62 to column 13, line 3) and in suppositories for a systemic effect due to the effect of transcutaneous absorption, such as in suppositories.

15           The patent provides at column 13, lines 5 to 31:  
"The vehicling action of the hyaluronic esters also applies to associated medicaments of the type mentioned above in which the active substance acts not only topically or by nasal or  
20 rectal absorption, for example by nasal sprays or preparations for inhalation for the oral cavity or the pharynx, but also by oral or parenteral route, for example by intramuscular, subcutaneous or intravenous route, as it favors absorption of  
25 the drug into the application site. The new medicaments can therefore be applied, apart from in the fields already mentioned, in practically all sectors of medicine, such as internal

medicine, for example in pathologies of the cardiovascular system, in infections of the respiratory system, the digestive system, the renal system, in diseases of an endocrinological nature, in oncology, in psychiatry etc., and may also be classified therefore from the point of view of their specific action, being perhaps anesthetics, analgesics, anti-inflammatories, wound healers, antimicrobics, adrenergic agonists and antagonists, cytostatics, antirheumatics, antihypertensives, diuretics, sexual hormones, immunostimulants and immunosuppressants, for example, one of the drugs having the activity already described for the therapeutically active alcohols to be used as esterifying component according to the present invention, or for the therapeutically active bases used for the salification of the free carboxylic groups."

There have been extensive studies to determine the defect in immune function that allows a tumour cell to develop. It was postulated initially by Jerne, and subsequently by Burnett, that the immune system's major role was that of immunological surveillance to destroy abnormal cells. The concept of surveillance, while somewhat simplistic, remains an accepted concept for the elaborate mechanism of immune recognition and function that is present in the higher species - mammals.

It has then been postulated that tumours develop

because of local or generalized immune suppression. However, as pointed out by Moller, if general immune suppression occurs, it is only certain types of neoplastic disorders that develop, mainly those of the lympho-reticular system. This observation is correct and represents a major challenge to the immune surveillance theory unless a specific reason can be shown as to why the individual cancer cell can develop plus individually evade the immune system.

It was demonstrated experimentally in 1974 that defects of macrophage function may exist in neoplastic disease.

The initial experiments found suppressor cells to be part of the immune system; these were either of the T-cell type of the macrophage cell system. There was presence demonstrated in neoplasia, chronic bacterial infection, recovery from massive injury and chronic fungal infection.

There has been repeated demonstration in experimental animals that the macrophage cell function is altered in neoplastic disease. The macrophages in the animal's systems appeared "blocked" in their function. Generally when removed from the *in vivo* situation, washed in saline and cultured, they could perform normally. This block has been shown to be related to the excessive production of prostaglandin by neoplastic tissue or by the macrophage itself. Similarly, the N.K. cells (which are said to be primitive or immature macrophages and which may be involved in cancer defence) are also blocked.

In the basic research efforts in the latter '70s and the early '80's, there existed considerable confusion as to what role immunotherapy should take in cancer. Activation or

"hyping" of macrophages was thought to be important. However, in an examination by Romans and Falk of peritoneal macrophages obtained from patients with neoplastic disease, there was definite evidence that these macrophages were already activated yet were co-existing with cancer cells and not causing their destruction.

It has recently been shown by several independent investigators that the malfunction of macrophages or the putative block is due to excessive prostaglandin and that this can be altered in tissue culture by corticosteroids, ASA, and the non-steroidal anti-inflammatory drugs, i.e. indomethacin and naproxen (Naprosyn<sup>TM</sup>). Again, it was repeatedly demonstrated that in animal tumours these substances could alter the response to neoplastic cells and that various combinations of these substances employed with immune enhancing agents could produce very credible success in eliminating experimental tumours. Lala and co-workers combined Indomethacin therapy with Interleukin 2 and showed that this could effect a cure with experiment neoplasm.

There were continued problems with the use of any of these agents in the actual human *in vivo* experience. All of the non-steroidal anti-inflammatory agents (NSAID) produced major toxicity in terms of gastro-intestinal, neurological, and other areas. Thus, the basis of the present approach is that, under general circumstances, with the use of these agents in human disease in sufficient amounts, the drug will penetrate to any pathological tissue to alter therapeutically local prostaglandin production. While intravenous preparations of Indomethacin (and

now of other agents) exist, using these drugs alone produces prohibitive side effects in human subjects. Therefore, only insufficient amounts can be brought into the body to effect more than occasional responses in neoplasm.

5           However, the majority of the evidence is present to indicate and therefore, it can be postulated that the basis for neoplastic development and how the initial cell "sneaks by" the immune surveillance mechanism relates to its production of prostaglandin. One need postulate only one mutation to alter  
10 the amount of prostaglandin synthesis produced by cells when they become "malignant" to establish a mechanism of blocking out the initial cell in any immune reaction, i.e. the macrophage. It therefore became essential to develop a combination of NSAIDs for clinical use to produce a major improvement in response in  
15 neoplastic disease and other conditions where excessive prostaglandin synthesis represents the basis of the pathogenesis of this disease state, i.e. arthritis and various others of the so-called connective tissue inflammatory disorders and/or auto-aggressive diseases.

20           See also:

1. Modulation of Immunity in Cancer Patients by Prostaglandin Antagonists, Immunity to Cancer II, Alan R. Liss, Inc.; and
2. Goodwin, J.S., (1981) Prostaglandin E and Cancer  
25 Growth Potential for Immunotherapy with Prostaglandin Synthesis Inhibitors, Augmentive Agents in Cancer Therapy, Raven Press, New York.

United States Patent 4,711,780 teaches a



pharmaceutical composition comprising Vitamin C, a zinc salt, and a sulfur amino acid for treating surface epithelium for epithelium regeneration. Hyaluronic acid may be added for applications in the reproductive tract.

5           Because of the side effects of the use of non-steroidal anti-inflammatory drugs (major toxicity in terms of gastro-intestinal, neurological, and other areas), use thereof should also be restricted (if possible) to the area of use without delivery to other areas which are not in need of  
10 treatment. Thus, if useful amounts of the non-steroidal anti-inflammatory drugs could be delivered to a site in need thereof without carriage of substantial amounts away from the site to be treated, then the use of a non-steroidal anti-inflammatory drug may have many other useful applications.

15   SUMMARY OF THE INVENTION

Applicants have now discovered that topically applied transdermally quick penetrating (best targeting the epidermis and subsequently remaining there for a prolonged period of time) combinations and formulations which employ, combine, or  
20 incorporate (as the case may be) a therapeutically effective non-toxic (to the patient) amount of a drug which inhibits prostaglandin synthesis, preferably a non-steroidal anti-inflammatory drug (NSAID), for example, diclofenac, indomethacin, naproxen, and (+/-) tromethamine salt of ketorolac  
25 (sold under the trademark Toradol™) together with an amount of hyaluronic acid and/or salts thereof (for example the sodium salt) and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub units of hyaluronic acid

(preferably hyaluronic acid and salts thereof), may be used to treat the disease and condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts (condy'loma acuminata) cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women, with dramatic success. Furthermore, application of the combinations and formulations are systemic independent (there is a lack of a blood level of the NSAID), quick to penetrate into the skin particularly to the epidermis and remain there for prolonged periods.

Thus, according to one aspect of the invention, Applicants have provided topically applied transdermally penetrating (best targeting the epidermis) systemic independent acting (not acting essentially through the blood) pharmaceutical combinations and formulations comprising, together with pharmaceutical excipients suitable for topical application, a therapeutically effective (to treat and resolve the disease and conditions of the skin and exposed tissue (for example basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin,

primary and metastatic melanoma in the skin, genital warts (condyloma acuminata) cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women), non-toxic (to the patient) amount of a drug which inhibits prostaglandin synthesis, preferably a non-steroidal anti-inflammatory drug (NSAID), for example, diclofenac, indomethacin, naproxen, and (+,-) tromethamine salt of ketorolac (sold under the trademark Toradol™) administered with, or carried in, an amount of hyaluronic acid and/or salts thereof (for example, the sodium salt) and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid (preferably hyaluronic acid and salts thereof) sufficient to facilitate the NSAID's quick penetration to the site in the skin (for example epidermis) or tissue of the disease or condition through the tissue to remain there for a prolonged period of time to block prostaglandin synthesis. This blockage of prostaglandin synthesis then unblocks the macrophages and permits the macrophages of the patient proximate the lesion (for example, the basal cell carcinoma) to destroy the lesion or condition. Treatment with the formulation and combination eliminates the condition without recurrence, even where the lesion has recurred a number of times after other unsuccessful treatments. Other non-steroidal anti-inflammatory drugs may be used such as other propionic acid derivatives, Ibuprofen, acetylsalicylic acid, piroxicam and flunixin.

When such combinations and formulations are applied to

the site of the disease or condition for example the basal cell carcinoma of the patient suffering from, the basal cell carcinoma over a period of time (for example, for a period of 2-4 weeks 3 times daily) the basal cell carcinoma is completely  
5 resolved and disappears.

According to another aspect of the invention, a method of treating a disease or condition of the skin or exposed tissue for example basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver"  
10 spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts (condyloma acuminata) cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis  
15 (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women, in a mammal is provided comprising administering topically to the mammal a combination comprising, together with pharmaceutical excipients suitable for topical application, a therapeutically  
20 effective (to treat and resolve the disease or condition for example basal cell carcinoma or other lesion), non-toxic (to the patient) amount of a drug which inhibits prostaglandin synthesis, preferably a non-steroidal anti-inflammatory drug (NSAID), for example, diclofenac, indomethacin, naproxen, and  
25 (+,-) tromethamine salt of ketorolac (sold under the trademark Toradol™) administered with, or carried in, an amount of hyaluronic acid and/or salts thereof (for example, the sodium salt) and/or homologues, analogues, derivatives, complexes,

esters, fragments, and/or sub-units of hyaluronic acid (preferably hyaluronic acid and salts thereof) sufficient to facilitate the drug's ( for example NSAID's) penetration to the site in the skin of the disease or condition to be treated through the tissue (including any scar tissue) at the site through the cell membrane, thereby blocking prostaglandin synthesis.

Thus, according to another aspect of the invention, the treatment may employ the use of the formulation or combination by applying the formulation or combination a number of times daily (for example, 3 times daily) for a period of time, for example, 2-4 weeks to clear the lesion.

One such formulation may comprise 3% diclofenac in a 2<sup>1</sup>/<sub>2</sub>% hyaluronic acid (sodium hyaluronate - molecular weight 661,600) gel formulation, with the excipients being glycerine (5%), benzyl alcohol (3%) (acting in part as a solubilizer and preservative), and sterile water (the balance).

Another such formulation may comprise 3% diclofenac in a 2<sup>1</sup>/<sub>2</sub>% hyaluronic acid (sodium hyaluronate - molecular weight 679,000) gel formulation with excipients being benzyl alcohol (1%) (a preservative), methoxypolyethylene glycol 350 (20%) (a solubilizer), and sterile water (the balance).

While the above formulations are suggested, provided these is sufficient hyaluronic acid (for example, sodium hyaluronate) to facilitate the penetration to the site in the skin (for example epidermis) of a sufficient amount of a drug which inhibits prostaglandin synthesis, preferably an NSAID (for example, diclofenac), to block prostaglandin synthesis, then the

formulations may be of any suitable form, for example, a lotion of hyaluronic acid, or cream or any suitable combination.

While higher molecular weights of the hyaluronic acid and forms thereof may be used and may penetrate more rapidly, where the molecular weight of the hyaluronic acid chosen for use is very large, there may not be as much penetration. Thus, the hyaluronic acid may be autoclaved, to break down the hyaluronic acid to fragments of lesser molecular weight. Furthermore, because there is little concern with respect to the toxicity or adverse effects with the use of, for example, the NSAIDs with the hyaluronic acid, after solubilizing the NSAID in a suitable solubilizer, the NSAID may be combined as needed.

According to another aspect of the invention, transdermal delivery of a therapeutically effective amount of a drug which inhibits prostaglandin synthesis, preferably a non-steroidal drug (NSAID) to the site in the skin to treat a disease or condition for example the basal cell carcinoma (or actinic keratoses lesion) in a mammal is provided, the delivery comprising topically administering (to for example the basal cell carcinoma or other lesion) a therapeutically effective non-toxic (to the patient) amount of an agent which inhibits prostaglandin synthesis, preferably an NSAID (non-steroidal anti-inflammatory drug), for example, diclofenac, indomethacin, naproxen, and (+/-) tromethamine salt of ketorolac (sold under the trademark Toradol™), with a sufficient amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and sub-units of hyaluronic acid, preferably hyaluronic acid and salts thereof,

sufficient to transport, or facilitate the transport of, the NSAID to the site of the disease or condition usually in the epidermis, for example the basal cell carcinoma (or other lesion) through the cell membranes into the individual cells to  
5 be treated to block the synthesis of prostaglandins.

Thus, according to another aspect of the invention, use of a combination or formulation is provided to treat the disease or condition for example the basal cell carcinoma (or other lesion), the combination and formulation comprising  
10 together with pharmaceutical excipients suitable for topical application, a therapeutically effective (to treat and resolve, for example, the basal cell carcinoma), non-toxic (to the patient) amount of an agent which inhibits prostoglandin synthesis preferably a non-steroidal anti-inflammatory drug  
15 (NSAID), for example, diclofenac, indomethacin, naproxen, and (+,-) tromethamine salt of ketorolac (sold under the trademark Toradol™) administered with, or carried in, an amount of hyaluronic acid and/or salts thereof (for example, the sodium salt) and/or homologues, analogues, derivatives, complexes,  
20 esters, fragments, and/or sub-units of hyaluronic acid (preferably hyaluronic acid and salts thereof) sufficient to facilitate the NSAID's penetration into the skin especially the epidermis through the tissue (including any scar tissue) at the site of the disease or condition for example basal cell  
25 carcinoma (or other lesion) to be treated, thereby blocking prostaglandin synthesis to enable the macrophages (and N.K. cells) to resolve the disease or condition for example basal cell carcinoma or other lesion.

Applicants postulate that the hyaluronic acid and/or salts thereof and/or the homologues, analogues, derivatives, complexes, esters, fragments, and/or sub units of hyaluronic acid facilitate the transport of the agent (preferably NSAID) to the site of prostaglandin synthesis to block prostaglandin synthesis and, at the same time, abate the pain the patient is experiencing at the paccinian nerve bundles (superficial nerve bundles).

By way of example and to illustrate the facilitation of the delivery or transport of a chemical to a site in a mammal, when ethyl alcohol is injected directly into a tumour and sonographic (ultrasound) assessment is made, it is not dispersed throughout the tumour. When the ethyl alcohol to be administered into a tumour is carried by hyaluronic acid and/or salts thereof, sonographic assessment of the tumour demonstrates the dispersion of the ethyl alcohol throughout the tumour.

While Applicants postulate that the hyaluronic acid facilitates the transport and delivery, Applicants' invention may be used as described irrespective of the actual method of operation of the hyaluronic acid and/or salts thereof and/or the homologues, analogues, derivatives, complexes, esters, fragments and sub-units of hyaluronic acid.

The combination of hyaluronic acid and salts thereof and other forms with drugs that inhibit prostaglandin synthesis, for example NSAIDs, alters their distribution and performance in the human body, permitting amounts of NSAIDs to be used that could otherwise cause severe side effects (because, in part, the combinations and formulations are systemic independent), and



produces an unusual targeting for underperfused tissue and/or pathological tissue.

As a major amount of soluble indomethacin may be required, the chemical product may be solubilized using n-methyl glucamine at a dilution of 5mg/ml of n-methyl glucamine (NMG). This substance is then passed through a 22 micron Milipore filter to produce sterility. This material is non-toxic at 16 fold the therapeutic dose in animals (with hyaluronic acid) and for this reason was considered appropriate to be used in human conditions. Thus, Indocid™ solubilized in NMG may be administered with hyaluronic acid topically for transdermal penetration at, for example, varying doses. The solution of indomethacin and NMG may be diluted with, for example, "LifeCore™" hyaluronic acid. This produces an appropriate mixture and can be administered safely. (Similar clinical studies have been done with hyaluronic acid prepared by other methods, i.e. extraction.)

When the NSAID, for example indomethacin (dissolved in n-methyl glucamine) or other NSAID, is applied topically in a formulation with the form of hyaluronic acid, no major toxic side effects occur, such as gastro-intestinal distress, neurological abnormalities, depression, etc., even at elevated amounts of indomethacin (if necessary). (This may be in part because of the clearing of the hyaluronic acid through the lymphatic system from the site). In addition, the responses that have been observed are dramatic when the NSAID (for example diclofenac) is combined with hyaluronic acid, demonstrating clearly that the combination is now "targeting" to the

pathological tissue. Furthermore, the patients using the formulations and combinations of NSAID - hyaluronic acid (sodium hyaluronate) (for example, diclofenac or indomethacin and hyaluronic acid), experience dramatic relief of pain immediately. Thus, Applicants believe that the use of the NSAID, for example with hyaluronic acid (sodium hyaluronate), deblocks the macrophages (and N.K. cells (Natural Killer Cells) thought to be immature macrophages) by preventing enzymatic production of prostaglandin which blocks macrophage (and N.K. cell) functioning. The hyaluronic acid (and salt and other forms) not only enhances the activity of the NSAID but also reduces any side effects and toxicity that is associated with the use of the prostaglandin synthesis inhibitors. When formulations and combinations of the NSAIDs (for example, diclofenac) with, for example, hyaluronic acid or the sodium salt thereof, are applied to for example the tumour lesion (for example basal cell carcinoma) or other condition (for example, actinic keratoses lesion) for a period of time (for example, 3 times daily for 2-4 weeks), the carcinoma and lesions, as the case may be, disappear.

Applicants also postulate that when the combination or formulation is applied to the disease or condition (for example, basal cell carcinoma or actinic keratoses), the hyaluronic acid passes between the cells (in the stratum corneum, epidermis, and dermis) to the areas deficient in hyaluronic acid (or forms thereof), taking, drawing, carrying or pulling the NSAID with it to the sites of prostaglandin synthesis, penetrating to inhibit prostaglandin synthesis. The NSAID now being proximate the

Paccinian nerve bundle (superficial nerve bundles at the end of the nerves) gives pain relief. The macrophages (which have been blocked) are then unblocked and act to destroy the disease or condition for example basal cell carcinoma, actinic keratoses lesion, or other disease or lesion. Furthermore, the combination or formulation, comprising the form of hyaluronic acid and NSAID passing through the stratum corneum, epidermis, and dermis, slowly passes through the skin, staying longer in the skin at the site. Therefore, after having an immediate effect (for example, relieving pain and acting on the basal cell carcinoma, actinic keratoses and other disease, condition or lesion), the NSAID-hyaluronic acid combination remains longer at the site in need of treatment before it is cleared, Applicants believe, through the lymphatic system.

Furthermore, according to another aspect of Applicant's invention, Applicant's formulations and combinations and use of the formulations and combinations quickly penetrates through the stratum corneum into the epidermis (and dermis) where it remains for a prolonged time for treatment.

Fifteen (15) minutes after application of one of Applicants' formulations, about three times the amount of Applicants' formulation has penetrated into the skin (particularly the epidermis) than formulations and combinations not containing hyaluronic acid but containing the same drug. Furthermore, the drug and hyaluronic acid remain at the site for a longer period of time.

Thus according to another aspect of the invention Applicants have provided a formulation and combination

comprising together with pharmaceutical excipients suitable for topical application, a therapeutically effective (to treat and resolve the disease and conditions of the skin and exposed tissue (for example basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women, non-toxic (to the patient) amount of a drug which inhibits prostaglandin synthesis, preferably a non-steroidal anti-inflammatory drug (NSAID), for example, diclofenac, indomethacin, naproxen, and (+,-) tromethamine salt of ketorolac (sold under the trademark Toradol™) administered with, or carried in, an amount of hyaluronic acid and/or salts thereof (for example, the sodium salt) and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid (preferably hyaluronic acid and salts thereof) sufficient to facilitate the NSAID's quick penetration to the site in the skin (for example epidermis) or tissue of the disease or condition through the tissue to remain there for a prolonged period of time to block prostaglandin synthesis. Thus the formulation or combination penetrates quickly into the skin, for example epidermis of the skin, accumulates there and remains there for a prolonged period of time, thereby accumulating the drug and

forms of hyaluronic acid in the skin (particularly the epidermis).

Thus according to another aspect of the invention, a method of accumulating a drug and a form of hyaluronic acid in the skin is provided comprising topically administering together with pharmaceutical excipients suitable for topical application, a therapeutically effective (to treat and resolve the disease and conditions of the skin and exposed tissue (for example basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women, a non-toxic (to the patient) amount of a drug for example which inhibits prostaglandin synthesis, preferably a non-steroidal anti-inflammatory drug (NSAID), for example, diclofenac, indomethacin, naproxen, and (+,-) tromethamine salt of ketorolac (sold under the trademark Toradol™) administered with, or carried in, an amount of hyaluronic acid and/or salts thereof (for example, the sodium salt) and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid (preferably hyaluronic acid and salts thereof) sufficient to facilitate the NSAID's quick penetration to the site in the skin (for example epidermis) or tissue of the disease or condition to remain there for a

prolonged period of time for example to block prostaglandin synthesis.

According to another aspect of the invention, a method of quickly delivering a drug to the skin, particularly the epidermis, and maintaining the drug therein for a prolonged period of time is provided, the method comprising topically administering together with pharmaceutical excipients suitable for topical application, a therapeutically effective (to treat and resolve the disease and conditions of the skin and exposed tissue (for example basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women, non-toxic (to the patient) amount of a drug for example which inhibits prostaglandin synthesis, preferably a non-steroidal anti-inflammatory drug (NSAID), for example, diclofenac, indomethacin, naproxen, and (+,-) tromethamine salt of ketorolac (sold under the trademark Toradol™) administered with, or carried in, an amount of hyaluronic acid and/or salts thereof (for example, the sodium salt) and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid (preferably hyaluronic acid and salts thereof) sufficient to facilitate the NSAID's quick penetration to the site in the skin

(for example epidermis) or tissue of the disease or condition through the tissue to remain there for a prolonged period of time (for example epidermis and dermis) to, for example block prostaglandin synthesis.

- 5 According to another aspect of the invention, a method of controlling the unloading of a drug from the skin or exposed tissue into the lymphatic system comprising delivering into the skin a drug and a form of hyaluronic acid comprising an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid.

We have compared the penetration and retention of one of our combinations (formulations) with a control and Voltarol Emulgel in the skin as follows:

15 (A) OUR FORMULATION

1% DICLOFENAC IN 3.0% HA GEL 50g/tube

EPDICLO1

LOT XPB 044

Quantity 1500ml

20	<u>FORMULA</u>	<u>Supplier</u>	<u>Lot</u>	<u>Amount</u>	<u>Percent</u>
	Sterile Water	Baxter	AW45F1	1397ml	--
	Glycerin	Life	1043	45g (36ml)	3%
	Benzyl Alcohol	Caledon	02517	22.5g (22ml)	1.5%
	Liquid Wax DICDD	Brooks	191-175	45g	3%
25	Diclofenac Sodium	Prosintex	9113003	15g	1%
	Sodium Hyaluronate	Skymart	HG-1103	45g	3%
	Mol. Wt. 661,600				

PROCEDURE

- 5 - Set up stirring apparatus using a 3 liter stainless steel beaker
- Add Water, Glycerin, Benzyl Alcohol and Liquid Wax DICDD, stir and mix for 10 minutes
- 10 - Add Diclofenac Sodium and stir for 30 minutes to dissolve
- Add Sodium Hyaluronate and stir for 90 minutes

15 FILLED

- In a 50 ml aluminum collapsible tube,  
inside of tube lacquered with a phenolic resin, outside of  
tube white regular enamel coating;
- 20 9 mm white polypropylene screw on cup with pierce tip

	Gels	Batch No.s
(B)	Voltarol Emulgel	060400 10 93
(C)	1% Diclofenac Gel	XPB049 ( <u>Control</u> )

25

(C) CONTROL1% DICLOFENAC IN CARAPOL GEL, 50g Jar

LOT XPB 049

Quantity 100ml

30	<u>FORMULA</u>	<u>Supplier</u>	<u>Lot</u>	<u>Amount</u>	<u>Percent</u>
	Sterile Water	Baxter	AW45N5	93ml	--
	Glycerin	BDH	2579	3g	3%
	Benzyl Alcohol	BDH	23797	1.5g	1.5%
	Liquid Wax DICDD	Brooks	L-1424	3g	3%
35	Diclofenac Sodium	Prosintex	9113003	1g	1%
	Carbopol 934	A&C Chemicals	910304	1g	1%

PROCEDURE

- Set up stirring apparatus using a 400ml stainless steel beaker

40



30

- Add Water, Glycerin, Benzyl Alcohol, Liquid Wax DICDD, and stir to mix thoroughly for 10 minutes
- Add Diclofenac Sodium and stir for 20 minutes to dissolve
- Very slowly add Carbopol 934, avoid getting lumps

## Samples

10	Cell	Sample	Quantity of gel applied (mg)
	A	060400 10. 93	192
	B	060400 10 93	192
	C	EPDICLO1*	192
15	D	EPDICLO1*	192
	E	XPB049	192
	F	XPB049	192

\* - Our Formulation

20 Skin Type

One piece of skin (Female, 37 years, smoker, breast skin) was used for one sample from each batch. A second piece of skin (no further details available) was used for the second sample from each batch. The skin was stored deep frozen (<- 20°C) until thawed for this experiment. Full thickness skin was used for this experiment.

Experimental Conditions

Skin permeation cells were prepared containing an exposed skin surface area of 9.6 cm<sup>2</sup> and a constantly stirred receptor fluid beneath the skin consisting of 135 ml of ethanol:phosphate buffered saline (25:75 v/v).

Each cell was allowed to equilibrate for 1 hour at 37°C after which the gel was spread evenly over the skin surface at a concentration of 20 mg/cm<sup>2</sup>). See table above.

The cell was then maintained at 37°C with an air temperature  
5 above the skin of 35°C.

24 hours after application of the gel the experiment was stopped and a portion of the receptor fluid removed. The skin was removed from the cell and any gel remaining on the surface carefully wiped off with dry paper towel followed by  
10 paper towel moistened with water. The skin was cut with a scalpel to obtain thin top and thicker lower sections of skin.

This was done in order to obtain layers of skin which approximated the epidermal and dermal layers. Each skin section was weighed and the residual diclofenac extracted with 10ml of  
15 fresh receptor fluid using an ultra turrax homogeniser. The homogenates were centrifuged and a portion of the resultant supernatant solutions removed.

The receptor fluid and skin extracts from each cell were assayed for diclofenac content by using a validated reverse  
20 phase high performance liquid chromatography (HPLC) method.

ResultsDistribution of Diclofenac 24 hours after application of Diclofenac Gel

5	Sample	Receptor	Top Skin portion			Bottom skin portion		
		µg	Skin Weight (g)	µg	µg/g	Skin Weight	µg	µg/g
10	(Voltarol Emugel)							
	060400 10 93	447	0.1363	101	742	1.2449	217	174
	060400 10 93	764	0.2445	141	577	1.2351	202	164
15	Mean	606			660			169
	(Our Formulation)							
20	EPDICLO1	247	0.1535	133	867	1.4663	148	101
	EPDICLO1	292	0.1647	145	879	1.0022	86	86
	Mean	269			873			93
25	(Control)							
	XPB049	184	0.1275	35	272	1.1324	58	51
	XPB049	147	0.2068	82	396	1.0893	68	63
	Mean	165			334			57
30								

Thus having regard to the above and Figures 1, 2 and 3, it is clear that the sodium hyaluronate takes the diclofenac into the skin to the epidermis level (See Figure 1) more rapidly than the Voltarol Emugel or non-hyaluronic acid diclofenac containing control formulation and retains it there longer. The other formulations take the NSAID, diclofenac, through the

bottom skin portion (dermis) quicker, thereby clearing it from the epidermis and dermis, quicker. Furthermore, more of Applicants' formulation is in the epidermis and in the dermis even after 12 hours.

5           It is also clear that Applicants' formulations clear into the lymphatic system not through the blood system. Yet the prior art topical formulations have always tried "to drive" the formulations through the skin into the blood for treatment of the disease or condition in the area (i.e. systemic action).

10           Thus, our formulation and combination, penetrates quickly and rapidly at the site of treatment through the upper skin into the epidermis, where the paccinian bundles are located and retain the NSAID and the form of hyaluronic acid longer, where needed (for example for the treatment of basal cell  
15 carcinoma).

          Further, the NSAIDs are retained in the area to be treated with the form of hyaluronic acid. In doing so, they preclude prostaglandin synthesis and, in effect, deactivate the synthesis or inhibit synthesis of prostaglandins, permitting the  
20 macrophages' scavenger cell activity to eliminate the tumour and lesion. Additionally, a rapid onset of pain relief (analgesic effect) is provided. However, there are no blood levels of the NSAID in the immediate area of treatment. The forms of  
hyaluronic acid, Applicants believe, are cleared via the  
25 lymphatic system. Then the lymphatics pass the forms of hyaluronic acid, Applicants believe, to the blood system. Thus, the NSAIDs and forms of hyaluronic acid stay at the site to be treated for well in excess of 12 - 24 hours, a protracted stay.

Thus, over the period of treatment (for example, application 3 times a day for 2-4 weeks) the NSAIDs penetrate sufficiently to inhibit prostaglandin synthesis to enable macrophages to "scavenge" the tumour cells and eliminate them.

5 The end result is the successful treatment of the disease or condition of the skin or exposed tissue for example the resolution of the basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the  
10 epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair  
15 loss on the head of pregnant women, with complete disappearance of the disease or condition as the case may be, by topical therapy without resorting to surgery.

One of the formulations which we have employed successfully is a gel formulation comprising 3% diclofenac in  
20 2.5% sodium hyaluronate formulated as follows:

Formulation 1 (3000 ml.)

	<u>Formula</u>	<u>Supplier</u>	<u>(LOT)</u>	<u>Amount</u>	<u>Percent</u>
25	Glycerine	Life	1043	150 g (119 ml)	5
	Benzyl Alcohol	Caledon	02517	90 g (86 ml)	3
	Diclofenac Sodium	Prosintex	9113003	90 grams	3
	Sodium Hyaluronate (MW 661,660)	Skymark	HG1003	75 grams	2.5
30	Sterile water	Baxter	AW4455	2795 ml.	balance

Procedure

- set up stirring apparatus using a 4 litre stainless steel beaker
- add water, Glycerine, and Benzyl Alcohol; stir to mix
- 5 - add Diclofenac Sodium and stir for 30 minutes
- then add the Sodium Hyaluronate and stir for 90 minutes
- initially, stir at a high torque but avoid splashing; as the gel thickens, stir at a lower torque

Another such formulation is:

10 Formulation 2

Formula	Supplier	(LOT)	Amount	Percent
Methoxypolyethylene Glycol 350	Sigma	34F-0266	300 g.	20
Benzyl Alcohol	BDH	23797	15 g.	1
Diclofenac Sodium	Prosintex	9123012	45 g.	3
Sodium Hyaluronate (MW 679,000)	Skymart	HG 1004	37.5 g.	2.5
20 Sterile Water	Baxter	AW45R6	1200 ml.	balance

Procedure

- set up stirring apparatus using a 3 litre stainless steel beaker
- 25 - add water, Methoxypolyethylene Glycol 350, and Benzyl Alcohol and stir for 20 minutes to mix
- add Diclofenac Sodium and stir for 30 minutes to dissolve
- add Hyaluronate Sodium slowly and stir initially at a high speed, but avoid splashing
- 30 - after addition, stir at a slower speed for 90 minutes; the

slower speed reduces the formation of air bubbles

- the result is a clear, transparent, viscous gel

Still other formulations are:

5 Formulation 3

3% Diclofenac in 2.5% HA Gel

Formula	Supplier	LOT	Amount	Percent
Sterile Water	Baxter	AW45K6	1200 ml	-
Methoxypolyethylene Glycol 350	Sigma	34F-0266	300G (273 ml)	20%
Benzyl Alcohol	BDH	23797	15G (14 ml)	1%
Diclofenac Sodium	Prosintex	9123012	45 g	3%
Sodium Hyaluronate	Skymart	HG 1004	37.5 g	2.5%

15 MW 679,000

Procedure

- Set up stirring apparatus using a 2 liter stainless steel beaker,
- Add water, Methoxypolyethylene Glycol 350, and Benzyl Alcohol and stir for 20 minutes to mix,
- Add Diclofenoc Sodium and stir for 30 minutes to dissolve,
- Add Hyularonate Sodium slowly and stir initially at a high speed, but avoid splashing,
- After addition, stir at a slower speed for 90 minutes, the slower speed reduces the formation of air bubbles,
- The results is a clear transparent, viscous gel.

Formulation 45% IBUPROFEN IN 3.0% HA GEL, 50 ml JAR

	<u>Formula</u>	<u>Supplier</u>	<u>LOT</u>	<u>Amount</u>	<u>Percent</u>
5	Sterile Water	Baxter	AW45R6	196 ml	--
	Meglumine	Falk	15684	11 g	5.5%
	Ibuprofen	BDH	19/241	10 g	5%
	Benzyl Alcohol	BDH	23797	2 g	1%
10	Glycerin	BDH	2579	2 g	1%
	Hyaluronate Sodium	Skymart	HG 1003	6 g	3%
	Mol Wt 661,600				

15

PROCEDURE

- Set up stirring apparatus using a 300 ml stainless steel beaker,
- Add Steril Water and Meglumine, and stir for 10 minutes,
- 20 - Add Ibuprofen and stir for 15 minutes,
- Add Benzyl Alcohol, followed by Glycerin and stir for 15 minutes,
- Finally, add Hyaluronate Sodium slowly and stir initially at a high torque to mix, but avoid splashing,
- 25 - As the gel thickens, stir at a slow speed for 90 minutes.

Formulation 52% PIROXICAM IN 2.5% HA GEL

	<u>Formula</u>	<u>Supplier</u>	<u>LOT</u>	<u>Amount</u>	<u>Percent</u>
	Sterile Water	Baxter	AW45R6	200 ml	--
30	Meglumine	Falk	15684	8 g	4%
	Piroxicam	AMSA	1-010	4 g	2%
	Hyaluronate Sodium	Skymart	HG 1003	5 g	2.5%
	MW 661,600				



PROCEDURE

- Set up stirring apparatus using a 300 ml stainless steel beaker,
- Add 200 ml of sterile water,
- Add 8 grams of Meglumine and dissolve,
- Very slowly add 4 grams of Piroxicam and stir for 20 minutes,
- Slowly add 5 grams of Hyaluronate Sodium and stir at high target,
- Stir for 90 minutes at a slower speed

COMMENTS

- A clear yellowish transparent gel

Formulation 6

5% IBUPROFEN CREAM, 50 ml JAR

## 20 OILY PHASE

	Formula	Supplier	LOT	Amount	Percent
	Liquid wax DICDD	Brooks	U-1424	450 g	15%
25	Brookswax D	Brooks	P-490	480 g	16%
	Glycerin	BDH	109109/2578	150 g (119 ml)	5%
	AQUEOUS PHASE				
	Sterile Water	Baxter	M445F1	1950 ml	--
	Meglumine	Falk	15684	150 g	5%
30	Ibuprofen	BKH	19/241	150 g	5%
	MW 200,00				
	Sodium Hyaluronate	Skymart	001	45 g	1.5%
	Preservative Suttocide A	Sutton	SH-107	9 g	0.3%

35

PROCEDURE

- A - Add all the ingredients of the oily phase A into a 4 liter stainless steel beaker, melt at 55°C, finally heat to 75°C when Aqueous Phase B is ready
- 5 B - Into a 3 liter stainless steel beaker, add 1950 ml water, set up, the stirring apparatus, add the Meglumine, stir to dissolve for 10 minutes,
- Slowly add Ibuprofen, stir to dissolve for 20 minutes,
  - Very slowly add Sodium Hyaluronate and stir for one
- 10 hour to dissolve all the Sodium Hyaluronate,
- Finally, heat to 75°C, with stirring for a total time of 30 minutes,
- POUR B INTO A, both at a temperature of 75°C, slowly
- Remove the heat source and stir with a strong vortex for
- 15 one hour,
- When the temperature has cooled down to 45°C add preservative Suttocide A,
  - Continue stirring at a slower speed until the temperature is 35°C,
- 20 - At 35°C remove the propeller, pour into 50 ml jars.

Formulation 71% DICLOFENAC IN 3% HA Gel, 50 ml jar

Quantity 3000ml

5	<u>Formula</u>	<u>Supplier</u>	<u>LOT</u>	<u>Amount</u>	<u>Percent</u>
	Sterile Water	Baxter	AW45R6	2796ml	-%
	Glycerin	BDH	2579	50g (71ml)	3%
10	Benzyl Alcohol	BDH	23797	45g (43ml)	1.5%
	Liquid wax DICDD	Brooks	191-175	90 g	3%
	Diclofenac Sodium	Prosintex	9113003	30 g	1%
	Hyaluronate Sodium	Skymout	HG 1004	90 g	3%
	MW 679,000				

15

PROCEDURE

- Set up stirring apparatus using a 4 liter stainless steel beaker.
- Add water, Glycerin, Benzyl Alcohol and Liquid wax DICDD and stir to mix thoroughly for 10 minutes
- 20 - Add Diclofenac Sodium and stir for 30 minutes to dissolve.
- Slowly add Hyaluronate Sodium, stirring at a high torque initially during addition.
- After addition stir at a slower speed for 90 minutes.
- 25 - A white opaque viscous gel is formed.

Formulation 81% DICLOFENAC IN 3.0% HA Gel. 50 ml tube

Quantity 1500 ml

5

<u>Formula</u>	<u>Supplier</u>	<u>LOT</u>	<u>Amount</u>	<u>Percent</u>
Sterile Water	Baxter	AW45F1	1397 ml	-%
Glycerin	Life	1043	45g (36 ml)	3%
10 Benzyl Alcohol	Caledon	02517	22.5g (22ml)	1.5%
Liquid wax DICDD	Brooks	191-175	45 g	3%
Diclofenac Sodium	Prosintex	9113003	15 g	1%
Sodium Hyaluronate	Skymart	HG 1003	45 g	3%
Mol. Wt. 661,600				

15

PROCEDURE

- Set up stirring apparatus using a 3 liter stainless steel beaker.
- Add water, Glycerin, Benzyl Alcohol and Liquiwax DICDD, stir to mix for 10 minutes.
- Add Diclofenac Sodium and stir for 30 minutes to dissolve.
- Add Sodium Hyaluronate and stir for 90 minutes.

20

Formulation 9HYANALGESE CREAM (L)

50 ml tube

Quantity 3000 ml

5 FORMULA

A. Oily Phase		SUPPLIER	LOT	AMOUNT	PERCENT
10	Liquid Wax DICDD	Brooks/Amisol		450g	15.0%
	Brookswax D	Brooks/Amisol		480g	16.0%
	Glycerine	Amisol		150g	5.0%
B. Aqueous Phase					
15	Sterile Water	Baxter	AW4YA8	1950ml	-%
	Meglumine	Falk		150g	5.0%
	Sodium Hyaluronate	Skymart	PO1	45g	1.5%
	MW 207,000				
	Ibuprofen	BDH		150g	5.0%
	Suttocide A	Sutton		9.0g	0.3%

20

PROCEDURE

- A. - Add all the ingredients of the oily phase into a 4 liter stainless steel beaker, melt at 55°C, finally heat to 75°C when aqueous phase is ready (at 75°C) to pour in.
- 25 B. - Into another 4 liter stainless steel beaker, add 1950 ml water.
- Set up the stirring apparatus and add the Meglumine
  - Stir to dissolve with high torque, then slowly add Ibuprofen
  - 30 - When the Ibuprofen is dissolved, slowly add Sodium Hyaluronate
  - Stir cold for one hour to dissolve all the ingredients
  - Finally heat to 75°C and stir thoroughly throughout a 30 minute period

## MIX B INTO A

- Slowly pour B into A (both at 75°C) with stirring
- Immediately remove the hot plate (heat) and stir
- Stir with a strong vortex for one hour
- 5 - When the temperature is 45°C, add the preservative  
Suttocide A
- Stir for about an hour to cool to 35°C
- At 35°C remove the propeller and pour into 50 ml tubes
- Pour 50 grams of the cream into each tube

10

## 1% BANAMINE IN 2.5% HA GEL

(L) XPB 041 Quantity 3000 ml

FORMULA

	SUPPLIER	LOT	AMOUNT	PERCENT
15	Sterile Water	Boxter	AW4SA2	2400 ml
	Sodium Hyaluronite	Skymart	HE1003	75g
	MW 661,600			--%
	*Banamine, 100 ml vial	Scheing	O CNXB13	300 ml
20	Banamine, 100 ml vial	Scheing	O CNXB12	300 ml
				1%
				1%
			3000 ml	
	(50 mg/ml) 600 = 30,000mg			
	= 30 grams Flunixin in 600 ml			
25	*Banamine contains Flunixin Meglumine (50 mg Flunixin per ml)			
	or 83 mg Flunixin Meglumine			

PROCEDURE

- Set up stirring apparatus using a 4 liter stainless steel beaker
  - 30 - Add water, stir with a strong vortex, then add sodium Hyaluronate slowly
  - Then immediately add the Banamine, stir the mixture for 4 hours.
- One form of hyaluronic acid and/or salts thereof (for
- 35 example sodium salt) and homologues, analogues, derivatives,

complexes, esters, fragments, and sub-units of hyaluronic acid, preferably hyaluronic acid and salts and thereof, suitable for use with Applicant's invention is a fraction supplied by Hyal Pharmaceuticals Limited. One such fraction is a 15 ml vial of  
5 Sodium hyaluronate 20mg/ml (300mg/vial - Lot 2F3). The sodium hyaluronate fraction is a 2% solution with a mean average molecular weight of about 225,000. The fraction also contains water q.s. which is triple distilled and sterile in accordance with the U.S.P. for injection formulations. The vials of  
10 hyaluronic acid and/or salts thereof may be carried in a Type 1 borosilicate glass vial closed by a butyl stopper which does not react with the contents of the vial.

The fraction of hyaluronic acid and/or salts thereof (for example sodium salt) and homologues, analogues,  
15 derivatives, complexes, esters, fragments, and sub-units of hyaluronic acid, preferably hyaluronic acid and salts thereof, may comprise hyaluronic acid and/or salts thereof having the following characteristics:

a purified, substantially pyrogen-free fraction of  
20 hyaluronic acid obtained from a natural source having at least one characteristic selected from the group consisting of the following:

- i) a molecular weight within the range of 150,000-225,000;
- 25 ii) less than about 1.25% sulphated mucopolysaccharides on a total weight basis;
- iii) less than about 0.6% protein on a total weight basis;

iv) less than about 150 ppm iron on a total weight basis;

v) less than about 15 ppm lead on a total weight basis;

5 vi) less than 0.0025% glucosamine;

vii) less than 0.025% glucuronic acid;

viii) less than 0.025% N-acetylglucosamine;

ix) less than 0.0025% amino acids;

x) a UV extinction coefficient at 257 nm of less than about 0.275;

10 xi) a UV extinction coefficient at 280 nm of less than about 0.25; and

xii) a pH within the range of 7.3-7.9.

Preferably, the hyaluronic acid is mixed with water and the fraction of hyaluronic acid has a mean average molecular weight within the range of 150,000-225,000. More preferably, the fraction of hyaluronic acid comprises at least one characteristic selected from the group consisting of the following characteristics:

20 i) less than about 1% sulphated mucopolysaccharides on a total weight basis;

ii) less than about 0.4% protein on a total weight basis;

25 iii) less than about 100 ppm iron on a total weight basis;

iv) less than about 10 ppm lead on a total weight basis;

v) less than 0.00166% glucosamine;



- vi) less than 0.0166% glucuronic acid;
- vii) less than 0.0166% N-acetylglucosamine;
- viii) less than 0.00166% amino acids;
- x) a UV extinction coefficient at 257 nm of  
5 less than about 0.23;
- xi) a UV extinction coefficient at 280 nm of  
less than 0.19; and
- xii) a pH within the range of 7.5-7.7

Other forms of hyaluronic acid and/or its salts, and  
10 homologues, derivatives, complexes, esters, fragments and sub  
units of hyaluronic acid may be chosen from other suppliers, for  
example those described in the prior art documents. In  
addition, Applicants have successfully employed sodium  
hyaluronate produced and supplied by LifeCore™ Biomedical,  
15 Inc., having the following specifications:

	<u>Characteristics</u>	<u>Specification</u>
	Appearance	White to cream colored particles
	Odor	No perceptible odor
20	Viscosity Average	< 750,000 Daltons
	Molecular Weight	
	UV/Vis Scan, 190-820nm	Matches reference scan
	OD, 260nm	< 0.25 OD units
	Hyaluronidase Sensitivity	Positive response
25	IR Scan	Matches reference
	pH, 10mg/g solution	6.2 - 7.8
	Water	8% maximum
	Protein	< 0.3 mcg/mg NaHy

Acetate < 10.0 mcg/mg NaHy

Heavy Metals, maximum ppm

As	Cd	Cr	Co	Cu	Fe	Pb	Hg	Ni
2.0	5.0	5.0	10.0	10.0	25.0	10.0	10.0	5.0

5 Microbial Bioburden None observed

Endotoxin < 0.07EU/mg NaHy

Biological Safety Testing Passes Rabbit Ocular Toxicity Test

Another form of sodium hyaluronate is sold under the name Hyaluronan HA-M5070 by Skymart Enterprises, Inc. having the following specifications:

#### Specifications' Test

#### Results

	Lot No.	HG1004
15	pH	6.12
	Chondroitin Sulfate	not detected
	Protein	0.05%
	Heavy Metals	Not more than 20 ppm
	Arsenic	Not more than 2 ppm
20	Loss on Drying	2.07%
	Residue on Ignition	16.69%
	Intrinsic Viscosity	12.75 dl/s (XW: 679,000)
	Nitrogen	3.14%
	Assay	104.1%
25	Microbiological Counts	80/g
	E. coli	Negative
	Mold and Yeast	Not more than 50/g

The following references teach hyaluronic acid, sources thereof, and processes of the manufacture and recovery thereof.

United States Patent 4,141,973 teaches hyaluronic acid fractions (including sodium salts) having:

10 "(a) an average molecular weight greater than about 750,000, preferably greater than about 1,200,000 - that is, a limiting viscosity number greater than about 1400 cm<sup>3</sup>/g., and preferably greater than about 2000 cm<sup>3</sup>/g.;

(b) a protein content of less than 0.5% by weight;

15 (c) ultraviolet light absorbance of a 1% solution of sodium hyaluronate of less than 3.0 at 257 nanometers wavelength and less than 2.0 at 280 nanometers wavelength;

20 (d) a kinematic viscosity of a 1% solution of sodium hyaluronate in physiological buffer greater than about 1000 centistokes, preferably greater than 10,000 centistokes;

25 (e) a molar optical rotation of a 0.1 - 0.2% sodium hyaluronate solution in physiological buffer of less than  $-11 \times 10^3$  degree - cm<sup>2</sup>/mole (of disaccharide) measured at 220 nanometers;

(f) no significant cellular infiltration of the vitreous and anterior chamber, no flare in the aqueous humour, no haze or flare in the vitreous,

and no pathological changes to the cornea, lens, iris, retina, and choroid of the owl monkey eye when one milliliter of a 1% solution of sodium hyaluronate dissolved in physiological buffer is implanted in the vitreous replacing approximately one-half the existing liquid vitreous, said HUA being

- (g) sterile and pyrogen free and
- (h) non-antigenic."

10

Canadian Letters Patent 1,205,031 (which refers to United States Patent 4,141,973 as prior art) refers to hyaluronic acid fractions having average molecular weights of from 50,000 to 100,000; 250,000 to 350,000; and 500,000 to 730,000 and discusses processes of their manufacture.

In order to determine the blood levels in patients using formulations made according to embodiments of the invention, a study of the pharmacokinetic profiles of two topical diclofenac formulations after repeat dosing were undertaken.

One such product was the product Voltarol Emulgel marketed in the United Kingdom by Geigy. The other was a Diclofenac preparation in Hyaluronic Acid.

This was an open, repeat dose, crossover comparison using a randomized balanced block in six healthy volunteers.

The study consisted of administration with one, two week period in between periods, each period lasting fourteen days. The test articles applied were for the first six days of

each period and the seventh day was study day during which the final application is made and blood samples taken.

The approximate duration of the study including pre and post study screening was six weeks.

5

Doses

Diclofenac with Hyaluronic Acid  
Dose: Approximately 2 g, three times daily  
Route: Topical

10

(W1)Voltarol Emulgel, Diclofenac diethylammonium salt 1.16g aqueous gel (Geigy)  
Dose: Approximately 2 g, three times daily  
Route: Topical (W1)

15

ADMINISTRATION: to suitable patients

Subjects applied one of the designated test articles topically to the calves and massaged into the skin, in a dose of approximately 2 g per application three times a day for six consecutive days. The size of a 2g dose was prepared by comparison with a silicone example given to each subject.

20

On the seventh day, the cream was applied once, in the same manner as before, under the supervision of the staff of the Clinical Investigation Unit.

After a washout period of one week the procedure was repeated with the alternate test article.

25

The following were the results of the tests:

(H = hyaluronic acid formulation)

(V = Voltarol Emulgel)

PERIOD 1

All concentrations ng ml - 1

5	SUBJECT	TIME POINT (hours)											
		0	0.25	0.5	1	2	3	4	5	6	8	10	12
10	H-1	10.3	7.1	6.4	ND	ND	5.4	6.5	5.1	ND	ND	ND	ND
	H-2	ND	5.1	ND	5.1	ND	ND	ND	ND	ND	5.1	ND	ND
	V-3	ND	ND	ND	5.5	5.2	ND	ND	ND	ND	ND	ND	ND
	H-4	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
	V-5	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
	V-6	ND	ND	ND	ND	ND	ND	ND	8.4	ND	ND	ND	ND

15 ND = NONE DETECTED ( $>5.0 \text{ ng ml}^{-1}$ )PERIOD II

All concentrations ng ml -1

20	SUBJECT	TIME POINT (hours)											
		0	0.25	0.5	1	2	3	4	5	6	8	10	12
25	V-1	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
	V-2	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
	H-3	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
	V-4	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
	H-5	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
30	H-6	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND

ND = NONE DETECTED ( $>5.0 \text{ ng ml}^{-1}$ )

Other tests were undertaken to determine blood levels  
 35 comparing Proflex (a formulation containing Ibuprofen) and the  
 following formulation containing hyaluronic acid and Ibuprofen.

HYANALGESE CREAM (L) X PB 022

- 50 ml tube

Quantity 3000 ml

FORMULA

	<u>A. Oily Phase</u>	<u>SUPPLIER</u>	<u>LOT</u>	<u>AMOUNT</u>	<u>PERCENT</u>
5	Liquid Wax DICDD	Brooks/Amisol		450g	15.0%
	Brookswax D	Brooks/Amisol		480g	16.0%
	Glycerine	Amisol		150g	5.0%
	<u>B. Aqueous Phase</u>				
	Sterile Water	Baxter	AW4YA8	1950ml	-%
10	Meglumine	Falk		150g	5.0%
	Sodium Hyaluronate	Skymart	PO1	45g	1.5%
	MW 207,000				
	Ibuprofen	BDH		150g	5.0%
15	Suttocide A	Sutton		9.0g	0.3%

The following were the results

## (A) PROFLEX

20	SUBJECT	Time after administration (Hours)												
	Number	PD	0	0.25	0.5	1	2	3	4	5	6	8	10	12
	1	ND	0.41	0.37	0.37	0.32	0.30	0.27	0.27	0.24	0.37	0.31	0.31	0.16
25	2	ND	0.12	0.12	0.08	0.11	0.12	0.12	0.07	0.08	0.09	0.08	ND	0.06
	3	ND	0.09	0.08	0.07	ND	ND	ND	ND	ND	ND	ND	ND	ND
	4	ND	0.12	0.14	0.16	0.11	0.11	0.25	0.24	0.17	0.13	0.16	0.11	0.13
	5	ND	0.14	0.19	0.19	0.15	0.16	0.16	0.14	0.12	0.11	0.13	0.13	0.07
	6	ND	0.11	0.09	0.09	0.06	0.07	0.05	0.05	0.05	ND	ND	ND	ND
30	Mean	0.00	0.17	0.17	0.16	0.13	0.13	0.14	0.13	0.11	0.12	0.11	0.09	0.07
	S.D.	0.00	0.12	0.10	0.11	0.10	0.10	0.10	0.10	0.08	0.13	0.11	0.12	0.06

## (B) HYALURONIC ACID AND IBUPROFEN

35	SUBJECT		Time after administration. (Hours)												
	Number	PD	0	0.25	0.5	1	2	3	4	5	6	8	10	12	
40	1	ND	0.11	0.11	0.12	0.08	0.08	0.09	0.11	0.12	0.08	0.11	0.16	0.14	
	2	ND	0.22	0.21	0.26	0.17	0.24	0.24	0.25	0.23	0.19	0.19	0.20	0.14	
	3	ND	0.17	0.10	0.12	0.09	0.08	0.07	0.06	ND	0.06	0.26	0.09	0.05	
	4	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
	5	ND	0.17	0.16	0.16	0.12	0.09	0.10	0.11	0.10	0.09	0.10	0.07	ND	
45	6	ND	0.07	0.07	0.09	ND	ND	ND	ND	ND	ND	ND	ND	ND	
	Mean	0.00	0.12	0.11	0.13	0.08	0.08	0.08	0.09	0.08	0.07	0.11	0.09	0.06	
	S.D.	0.00	0.08	0.07	0.08	0.06	0.08	0.08	0.09	0.09	0.07	0.10	0.08	0.07	

ND None detected &lt;0.05 µg/ml

50

The above clearly indicates that the blood levels are much less using hyaluronic acid to administer the NSAID.

EXAMPLES

The following examples are offered to illustrate uses of Applicants' invention.

5 Example 1

A male patient had a number of lesions (basal cell carcinoma), including one on his forehead which was a combination of major "horny epithelium" and some degree of ulceration. After continuous treatment with Formulation 1  
10 (several times per day for several weeks), the lesions showed epithelialization, no hemorrhagic areas, and no initiated areas (as they were in the past without our treatment). The "horny epithelium" and ulceration of the forehead lesion were also gone. The patient had a complete successful response with the  
15 formulation. All basal cell carcinoma lesions had been resolved and disappeared. There has been no recurrence.

Example 2

60 year old male tennis player had sore elbow and basal cell carcinoma on forearm proximate sore elbow. Patient  
20 tried Formulation 1 to abate pain in tennis elbow. (Dr. Falk was not treating this patient for anything at the time and merely offered the formulation for pain relief of the elbow.) However, the formulation "spilled" over onto the Patient's basal cell carcinoma. Patient was planning to have basal cell  
25 carcinoma removed surgically by another doctor, but when he came in to see the doctor, the basal cell carcinoma was disappearing (because of spill-over of Formulation 1). Treatment was now undertaken by Dr. Falk with direct application of Formulation 1



to the lesion 3 times a week for two additional weeks. After two weeks, the basal cell carcinoma disappeared. There has been no recurrence.

Example 3

5                   Male, mid to late 40's had severe basal cell carcinoma on left temple. Doctors recommended its removal by surgery. However, the surgery would have been risky because of the lesion's proximity to facial nerves.

                  Patient saw Dr. Falk who gave him Formulation 2 to be  
10   applied 3 times daily.

                  After 14 days, 75% of the lesion was gone. Surgery was postponed and the treatment was continued. Application of Formulation 2 continued for an additional two weeks. At the end of the 2- week period, the lesion was completely resolved and  
15   disappeared without any surgery being required. There has been no recurrence.

Example 4

                  Male, early 40's, had recurrent actinic keratoses lesion on his right temple. Early attempts at removal by third  
20   parties involved the application of liquid nitrogen (twice) without final resolution. The lesion kept recurring. The patient was sent to Dr. Falk who treated the lesion with Formulation 1 with applications 3 times daily for 7 days. After 7 days, the lesion was completely resolved with no subsequent  
25   recurrence.

Example 5

                  A male patient suffering from kyphosis suffered from constant back pain. Taking analgesics orally and rubbing back

preparations onto his back did little to alleviate the back pain. When NSAIDs in hyaluronic acid (sodium hyaluronate) were applied directly to the back, the back pain eased and disappeared.

5           With indomethacin (dissolved in N-methyl glucamine) and naproxen both dissolved in hyaluronic acid, the patient experienced some side effects. However, with Toradol™ (the [ +/- ] form tromethamine salt of ketorolac - a prostaglandin biosynthesis inhibitor and analgesic and anti-inflammatory, the  
10 back pain eased and disappeared for some time and there were no side effects.

Example 6

A male patient with basal cell carcinoma was first treated by an oncologist who attempted to surgically excise the  
15 lesion (without success) and then irradiated the lesion again without success. The patient then attended before Dr. Falk who applied Applicant's formulation (diclofenac with sodium hyaluronate and excipients). Application was made three times daily for about a month and the lesion disappeared. Some  
20 excoriation anterior and slightly superior developed over the last two weeks but was cleared by the application of hyaluronic acid by itself.

This resolution clearly indicates that even with prior applications of unsuccessful therapies (surgery and  
25 irradiation), Applicant's formulations can be used successfully.

Example 7

In another patient, a drug (methotrexate) was carried in hyaluronic acid and applied topically to a patient with

psoriasis. The formulation was absorbed and the psoriasis cleared.

Example 8

A patient with dermal (skin) metastases in a fibratic  
5 scar form and metastatic cancer in the form of musculoskeletal  
involvement in her thorax.

On topical application of our formulation comprising  
diclofenac (Voltaren) in hyaluronic acid (sodium hyaluronate),  
her pain decreased dramatically and her skin and bone  
10 involvements steadily improved.

As many changes can be made to the invention without  
departing from the scope of the invention, it is intended that  
all material contained herein be interpreted as illustrative of  
the invention and not in a limiting sense.

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE AS FOLLOWS:

1. A topically applied transdermally penetrating systemic independent acting pharmaceutical combination and formulation for the treatment of a disease or condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts (condyloma acuminata) cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women, comprising, together with pharmaceutical excipients suitable for topical application, a therapeutically effective non-toxic amount of a drug which inhibits prostaglandin synthesis administered with, or carried in, an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid (preferably hyaluronic acid and salts thereof) sufficient to facilitate the drug's penetration through the skin and tissue (including any scar tissue) at the site requiring treatment, to block prostaglandin synthesis.

2. The combination or formulation of Claim 1 wherein the drug is a non-steroidal anti-inflammatory drug (NSAID).

3. The combination or formulation of Claim 2 wherein the hyaluronic acid and/or salts thereof (for example, the sodium salt) and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid is hyaluronic acid or a salt thereof.
4. The formulation or combination of Claim 3 wherein the NSAID is selected from diclofenac, indomethacin, naproxen, and (+,-) tromethamine salt of ketorolac.
5. The formulation or combination of Claim 3 wherein the NSAID is selected from IBUPROFEN, PIROXICAM, Propionic Acid derivatives, acetylsalicylic acid and Flunixin.
6. A method of treating a disease or condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts (condyloma acuminata) cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women, in a mammal which comprises administering topically to the mammal a combination comprising, together with pharmaceutical excipients suitable for topical application, a therapeutically effective (to treat and resolve the disease, condition or lesion), non-toxic (to the patient) amount of a drug which inhibits prostaglandin synthesis administered with, or carried in, an

amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid sufficient to facilitate the drug's penetration through the skin and tissue (including any scar tissue) at the site to be treated to block prostaglandin synthesis.

7. The method of Claim 6 wherein the treatment is applied daily for a number of weeks.
8. The method of Claim 6 wherein the hyaluronic acid and salts thereof (for example, the sodium salt) and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid is hyaluronic acid or a salt thereof.
9. The method of Claim 8 wherein the drug is a non-steroidal anti-inflammatory drug (NSAID).
10. The method of Claim 9 wherein the NSAID is selected from diclofenac, indomethacin, naproxen, and (+,-) tromethamine salt of ketorolac.
11. The method of Claim 9 wherein the NSAID is selected from IBUPROFEN, PIROXICAM, Propionic Acid derivatives, acecytylsalicylic acid and Flunixin.
12. The method of Claim 7 wherein the hyaluronic acid and salts thereof (for example, the sodium salt) and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or

sub-units of hyaluronic acid is hyaluronic acid or a salt thereof.

13. The method of Claim 12 wherein the drug is a non-steroidal anti-inflammatory drug (NSAID).

14. The method of Claim 13 wherein the NSAID is selected from diclofenac, indomethacin, naproxen, and (+,-) tromethamine salt of ketorolac.

15. The method of Claim 13 wherein the NSAID is selected from IBUPROFEN, PIROXICAM, Propionic Acid derivatives, acetylsalicylic acid and Flunixin.

16. Transdermal delivery of a therapeutically effective amount of a drug which prohibits prostaglandin synthesis applied topically to treat a disease or condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts (condyloma acuminata) cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women, in a mammal, the delivery comprising administering topically a therapeutically effective (to treat the disease or condition of the skin or exposed tissue) non-toxic (to the patient) amount of such drug with a sufficient amount of hyaluronic acid and/or

salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and sub-units of hyaluronic acid sufficient to transport, or facilitate the transport of, the drug to the site to block prostaglandin synthesis.

17. The delivery of Claim 16 wherein the hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and sub-units of hyaluronic acid, preferably hyaluronic acid and salts thereof is selected from hyaluronic acid and/or salts thereof.

18. The delivery of Claim 17 wherein the drug is a non-steroidal anti-inflammatory agent (NSAID).

19. The delivery of Claim 18 wherein the NSAID is selected from diclofenac, indomethacin, naproxen, and (+,-) tromethamine salt of ketorolac.

20. The delivery of Claim 18 wherein the NSAID is selected from IBUPROFEN, PIROXICAM, Propionic Acid derivatives, acetylsalicylic acid and Flunixin.

21. Use of a combination or formulation to treat a disease or condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts (condyloma acuminata) cervical cancer, and HPV (Human Papilloma



Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women, the combination and formulation comprising, together with pharmaceutical excipients suitable for topical application, a therapeutically effective (to treat and resolve the condition or disease of the skin or exposed tissue), non-toxic (to the patient) amount of a drug which inhibits prostaglandin synthesis administered with, or carried in, an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid sufficient to facilitate the drug's penetration through the skin and tissue (including any scar tissue) at the site to be treated to block prostaglandin synthesis.

22. The use of Claim 21 wherein the hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and sub-units of hyaluronic acid, preferably hyaluronic acid and salts thereof is selected from hyaluronic acid and/or salts thereof.

23. The use of Claim 21 wherein the drug is a non-steroidal anti-inflammatory agent (NSAID).


24. The use of Claim 23 wherein the NSAID is selected from diclofenac, indomethacin, naproxen, and (+,-) tromethamine salt of ketorolac.

2061566

- 63 -


25. The use of Claim 23 wherein the NSAID is selected from  
- IBUPROFEN, PIROXICAM, Propionic Acid derivatives,  
aceetylsalicylic acid and Flunixin.

2061566




**FIGURE 1**

2061566



**FIGURE 2**

2061566



**FIGURE 3**

PATENT COOPERATION TREATY



Registered letter

HUGHES ETIGSON  
175 Commerce Valley Drive West  
Suite 200  
THORNHILL, ONTARIO L3T 7P6  
CANADA

FROM THE INTERNATIONAL PRELIMINARY  
EXAMINING AUTHORITY

**NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT**  
Issued pursuant to PCT Rule 61.1

Inscribe NAME and ADDRESS of the AGENT  
or if there is no agent, of the APPLICANT

DATE OF MAILING by the International Preliminary  
Examining Authority

18.08.92

APPLICANT's or AGENT's FILE REFERENCE

PT-0800

**IDENTIFICATION OF THE INTERNATIONAL APPLICATION**

International Application No.

PCT/CA 90/00306

International Filing Date

18/09/1990

Applicant (Name)

NORPHARMCO INC. et al

**NOTIFICATION**

The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the above-identified international application.

The attention of the applicant is drawn to the reminder contained in Form PCT/IB/332, which he received from the International Bureau, concerning the time limits within which he must perform certain acts before each elected Office.

A copy of the report and its annexes, if any, has this same day also been transmitted to the International Bureau.

**THE INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY**

Name and Mailing Address

European Patent Office  
Erhardtstraße 27  
D-8000 München 2

Authorized Officer

N. Rolis



**PATENT COOPERATION TREATY  
INTERNATIONAL PRELIMINARY EXAMINATION REPORT**

<b>IDENTIFICATION OF THE INTERNATIONAL APPLICATION</b>		Applicant's or Agent's File Reference PT-0800	
International Application No. PCT/CA 90/00306	International Filing Date 18/09/1990	Date demand submitted 15/05/1991	
Receiving Office RO/CA	Priority Date Claimed 21/09/1989		
Applicant (Name) NORPHARMCO INC. et al			
<b>BASIS OF REPORT</b>			
<b>1. AMENDMENTS AND/OR RECTIFICATIONS</b> <sup>1</sup> - The amendments and/or rectifications made before this International Preliminary Examining Authority in respect of the claims, the description, and/or drawings in the above-identified International application are annexed to this report.			
a) <input checked="" type="checkbox"/> This report has been established on the basis of the following application documents:			
<input type="checkbox"/> the application documents as filed			
<input checked="" type="checkbox"/> description, pages 1 - 69			
description, pages			
description, pages			
description, pages			
<input checked="" type="checkbox"/> claim(s) 1 - 86			
claim(s)			
claim(s)			
claim(s)			
<input type="checkbox"/> drawings, sheet/fig.			
drawings, sheet/fig.			
as originally filed			
filed with your letter of			
filed with your letter of			
filed with your letter of			
as originally filed			
filed with your letter of 23/07/92			
filed with your letter of			
filed with your letter of			
filed with your letter of			
as originally filed			
filed with your letter of			
b) <input type="checkbox"/> The amendments resulted in the cancellation of the following sheets: .....			
c) <input type="checkbox"/> This report has been established as if the amendments indicated on the extra sheet have not been made, since, for the reasons indicated, they have been considered to go beyond the disclosure as filed.			
<b>2. PRIORITY</b> <sup>2</sup>			
a) This report has been established as if no priority has been claimed due to the failure to furnish within the prescribed time limit the requested:			
<input type="checkbox"/> copy of the earlier application whose priority has been claimed.			
<input type="checkbox"/> translation of the earlier application whose priority has been claimed.			
b) <input type="checkbox"/> This report has been established as if no priority has been claimed due to the fact that the priority claim has been found invalid.			
Thus, for the purposes of this report, the International filing date indicated above is considered to be the relevant date.			
* Where replacement sheets are annexed to this report, a translation of these replacement sheets must be furnished to the elected Offices within the time limit applicable under PCT Article 39(1).			

**FURTHER INFORMATION CONTINUED FROM THE FIRST SHEET**



**BASIS OF REPORT (Continued)**

3: UNITY OF INVENTION<sup>3</sup> - The international application does not comply with the requirement of unity of invention.

a) In response to an invitation to restrict or pay additional fees the applicant has

☐ restricted the claims.

☐ paid additional fees.

☐ paid additional fees under protest. Where requested by the applicant, the text of the protest together with the decision taken thereon are annexed to this report.

☐ neither restricted nor paid additional fees.

b) ☐ No invitation has been issued. The opinion of this International Preliminary Examining Authority is that the international application does not comply with the requirement of the unity of invention for the following reasons (specify).

c) Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report :

☐ all parts

☐ the parts relating to the restricted claims, that is claims Nos. \_\_\_\_\_.

☐ the parts relating to the main invention, that is claims Nos. \_\_\_\_\_.

**4. NON-ESTABLISHMENT OF REPORT ON QUESTIONS OF NOVELTY, INVENTIVE STEP OR INDUSTRIAL APPLICABILITY<sup>4</sup>**

The questions of whether the claimed invention appears to be novel, to involve an inventive step or to be industrially applicable have not for the reasons indicated been gone into respect of :

a) ☐ the entire international application

b) ☐ the claims Nos. \_\_\_\_\_

for the following reasons :

☐ Said international application, or said claims Nos. \_\_\_\_\_ relate to the following subject matter which does not require an international preliminary examination (specify) :

☐ The description, claims, or drawings (indicate particular elements) or said claims Nos. \_\_\_\_\_ are so unclear that no meaningful opinion can be formed.

☐ The claims, or said claims Nos. \_\_\_\_\_ are so inadequately supported by the description that no meaningful opinion could be formed.

☐ Said claims Nos. \_\_\_\_\_ are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4 (a)

**CLASSIFICATION OF SUBJECT MATTER**  
 (if several classification symbols apply, indicate all.)<sup>5</sup>

According to International Patent Classification (IPC) or both National Classification and IPC

A 61 K 47/36

**REASONED STATEMENT AS TO CLAIMS MEETING  
 CRITERIA OF NOVELTY (N), INVENTIVE STEP (IS) AND INDUSTRIAL APPLICABILITY (IA)<sup>6</sup>  
 AND CITATIONS<sup>7</sup> AND EXPLANATIONS<sup>8</sup> SUPPORTING SUCH STATEMENT**

CLAIM NUMBER	STATEMENT (CRITERIA)	CITATIONS AND EXPLANATIONS
1 - 86	N IS } IA }      yes	See separate sheet

**NON-WRITTEN DISCLOSURES<sup>9</sup>**

Kind of Non-Written Disclosure	Date of Written Disclosure, referring to the Non-Written Disclosure	Date of Non-Written Disclosure

**CERTAIN PUBLISHED DOCUMENTS<sup>10</sup>**

Application / Patent	Date of Publication	Filing date	Priority Date (valid claim)



**CERTAIN DEFECTS IN THE INTERNATIONAL APPLICATION<sup>11</sup>**

The following defects in the form or contents of the international application have been noted.

**CERTAIN OBSERVATIONS ON THE INTERNATIONAL APPLICATION<sup>12</sup>**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description have been noted.

**CERTIFICATION**

Date Demand Submitted  15.05.91	Date of Completion of the International Preliminary Examination Report  18.08.92
International Preliminary Examining Authority   <b>European Patent Office</b> Erhardtstraße 27 D-8000 München 2 ☎ 089 / 2399-0 Tx 523 656 epmu d FAX 089 / 23 99-44 65	Signature of Authorized Officer  

1). Concerning sections VI to VIII

Documents D1 (EP-A-0,265,116) and D2 (EP-A-0,216,453) disclose esters of hyaluronic acid forming pharmaceuticals (See D1 claims 14 and D2 claims 8, 13 and 14) . The two independent claims (1 and 44) of the present application are novel over these disclosures as the pharmacologically active agents and the hyaluronic acid components are separate. D1 and D2 disclose admixtures of the esters and active agents, but give no specific dosage or use.

Document D3 (EP-A-0,197,718) discloses a topical pharmaceutical containing hyaluronic acid and numerous drugs (See pages 7 and 8). D3 gives examples of formulations containing hyaluronic acid. However no specific dosage is given in D3, which details only the amounts of acid in topical formulations. It is not known from D3 how much of each topical formulation is to be applied. The man skilled in the art would not inevitably arrive at a result within the scope of the present claims.

The independent claims of the present application, which detail a dosage amount of hyaluronic acid are therefore to be considered as strictly novel.

From D3 it is clear that the hyaluronic acid is being used as an agent to promote the bioavailability of drugs by holding them in an elastic viscose form which adheres well to the tissue concerned. (See page 2 second paragraph). The applicant have shown in their numerous examples that at the claimed dosages the hyaluronic acid can increase the activity of many drugs by facilitating their uptake, not only in topical applications (see in particular case XXIX). This result would not have been expected by the man skilled in the art based on the topical formulations of D3 and/or the esters of D1 and D2.

The Independent claims therefore meet the requirements of Article 33 PCT.

Accordingly the dependent claims can be regarded as novel and inventive under Article 33 PCT.

**CLAIMS:**

1. A pharmaceutical composition comprising
  - (1) a medicinal and/or therapeutic agent in a therapeutically effective amount to treat a disease or condition in humans
  - and (2) hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and subunits of hyaluronic acid,characterized in that said composition
  - (a) is in a dosage form which is suitable for administration in humans;
  - and (b) is in a form in which (i) component (1) is in an effective dosage amount to treat said disease or condition by penetration at the site to be treated, and (ii) component (2) is available to transport component (1) at the site to be treated, and which component (2) is in an amount greater than 10 mg/70 kg person to facilitate the transport of component (1) upon administration, through the tissue (including scar tissue) at the site to be treated through the cell membranes into the individual cells to be treated, for use as a medicament.
2. A composition according to Claim 1 characterized in that component (2) is hyaluronic acid and/or salts thereof.
3. A composition according to Claim 1 or Claim 2 in liquid form immediately available for penetration at a site to be treated.

**SUBSTITUTE SHEET**

4. A composition of any preceding claim wherein component (2) is utilized at a dose between 10 mg and 1000 mg/70 kg person.
5. A composition of Claim 1, Claim 2, or Claim 3 wherein component (2) is present at a dose greater than 50 mg/70 kg person.
6. A composition of any preceding claim wherein component (2) is present at a dose between 50 mg and 1000 mg/70 kg person.
7. A composition of Claim 1, Claim 2, Claim 3, or Claim 5 wherein component (2) is present at a dose greater than 200 mg/70 kg person.
8. A composition of any preceding claim wherein component (1), the medicinal and/or therapeutic agent, comprises an agent selected from a free radical scavenger, ascorbic acid, Vitamin C, an anti-cancer agent, a chemotherapeutic agent, anti-viral agents, non-steroidal anti-inflammatory drugs (NSAID), steroidal anti-inflammatory drugs, an anti-fungal agent, detoxifying agents, analgesic, a bronchodilator, an anti-bacterial agent, antibiotics, drugs for the treatment of vascular ischemia, an anti-body monoclonal agent, diuretics, immunosuppressants, lymphokynes, alpha-and- $\beta$ -interferon, insulin, estrogen, progestegen, anti-metabolites, calcium channel blockers, drugs for the treatment of psoriasis, an anti-cholinergic drug, histamine, H<sub>2</sub> receptor antagonist, and combinations thereof.
9. A composition of Claim 7 wherein component (1) is a non-steroidal anti-inflammatory drug (NSAID).
10. A composition of any preceding claim wherein component (2) is separate from component (1).

SUBSTITUTE SHEET

11. A composition according to Claims 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for the treatment of psoriasis, a therapeutically effective amount of methotrexate with an amount of component (2) to facilitate the transport of the methotrexate upon administration, through the tissue of the site to be treated through the cell membranes into the cells to be treated.
12. A composition according to Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for administration to a human, a cytotoxic chemotherapeutic agent selected from adriamycin, methotrexate, mitomycin C, bleomycin, 5-fluorouracil, novantrone, carbo and cis platinum, and combinations thereof with an amount of component (2) to facilitate the transport of the cytotoxic chemotherapeutic agent upon administration through the tissue of the site to be treated through the cell membranes into the individual cells to be treated.
13. A composition according to Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for administration to a human, an agent selected from phloridzin, phloretin, and 5-deoxyglucuronide of phloridzin, and combinations thereof, to competitively block glucose transport in neoplastic cells, and an agent selected from Vitamin C and a non-steroidal anti-inflammatory drug, and combinations thereof, and an amount of component (2) to facilitate the transport of the agent upon administration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated and where phloretin is the selected agent, it is solubilized by a solubilizing agent.
14. A composition according to Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for administration to a human, a therapeutically effective amount of a diuretic with component (2) to facilitate the transport of the agent



through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.

15. A composition according to Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for administration to a human, a therapeutically effective amount of component (1) (a medicinal and/or therapeutic agent) selected from an antibiotic and anti-bacterial agent, and an amount of component (2) exceeding 10 mg to facilitate the transport of the agent through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.
16. A composition according to Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for internal administration to a human, a therapeutically effective amount of a non-steroidal anti-inflammatory drug (NSAID) with an amount of component (2) to facilitate the transport of the agent through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.
17. The composition of Claim 16 wherein the amount of component (2) exceeds 50 mg/70 kg person.
18. The composition of Claim 16 wherein the amount of component (2) is present in an amount between 50 mg and 1000 mg/70 kg person.
19. The composition of Claim 16 wherein the amount of component (2) exceeds 200 mg/70 kg person.
20. A composition according to Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for external administration to a mammal, a therapeutically

effective amount of a non-steroidal anti-inflammatory drug (NSAID) with an amount of component (2) to facilitate the transport of the agent through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.

21. The composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 wherein the amount of component (2) exceeds 50 mg/70 kg person.
22. The composition of 1, 2, 3, 4, 5, 6, 7, or 8 wherein the amount of component (2) is present in an amount between 10 and 1000 mg/70 kg person.
23. A composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for the treatment of a person with cancer, a therapeutically effective amount of component (1) selected from ascorbic acid (Vitamin C), non-steroidal anti-inflammatory drugs, and combinations thereof, and an amount of component (2) to facilitate the transport of the agent at a site to be treated through the tissue (including scar tissue) through cell membranes into the individual cells to be treated.
24. A composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for the treatment of cancer, the combination of a therapeutically effective amount of component (1) selected from ascorbic acid, a non-steroidal anti-inflammatory drug, an anti-cancer drug, a chemotherapeutic agent, a detoxifying drug, and combinations thereof, and an amount of component (2) to facilitate the transport of the agent through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated.

25. A composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for the treatment of renal failure, cardiac insufficiency, hypertension and edema, an effective amount of a diuretic and an amount of component (2) to facilitate the transport of the diuretic through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated.
26. The composition of Claim 25 wherein the diuretic is furosemide.
27. A composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for the treatment of infection a therapeutically effective amount of component (1) selected from antibiotics, antibacterials, antimicrobials and combinations thereof with or without ascorbic acid and an amount of component (2) to facilitate the transport of the agent through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated.
28. A composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for treating inflammation, a therapeutically effective amount of a non-steroidal anti-inflammatory drug (NSAID) and an amount of component (2) to facilitate the transport of the agent through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated.
29. A composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for use in assisting in the elimination of tumor breakdown material (including toxins, residue and debris) in a person suffering from tumors, a therapeutically effective amount of a non-steroidal anti-inflammatory drug (NSAID) and an amount of component (2) to facilitate the transport of the agent to penetrate at the site to be treated through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated.

- 7 -

30. A composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for detoxifying a patient of toxins, the combination of a therapeutically amount of a detoxifying agent and an amount of component (2) to facilitate the transport of the agent through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated.

31. A composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for use to treat infections surrounding implants in a patient, a therapeutically effective amount of an antibiotic for treating the infected tissue surrounding the implant and an amount of component (2) to facilitate the transport of the agent through the tissue at the site to be treated through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated.

32. A composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for the treatment of a patient suffering from cancer, a therapeutically effective amount of an agent selected from a non-steroidal anti-inflammatory agent, a therapeutically effective amount of an anti-cancer agent, and combinations thereof, and an amount of component (2) to facilitate the transport of the agent through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated.

33. The composition of Claim 32 further comprising a therapeutically effective amount of ascorbic acid (Vitamin C).

34. A composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for use to treat pain, a therapeutically effective amount of a non-steroidal anti-inflammatory agent and an amount of component (2) to facilitate

**SUBSTITUTE SHEET**

- 8 -

the transport of the agent at the site to be treated through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated.

35. A composition according to Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted to provide enhanced neoplastic activity and effect, a therapeutically effective amount of ascorbic acid and an amount of component (2) to facilitate the transport of the agent at the site to be treated through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated.

36. A composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for increasing the activity of the macrophages in mammals suffering from a disease, an effective amount of a non-steroidal anti-inflammatory agent (NSAID) and an amount of component (2) to facilitate the transport of the agent at the site to be treated through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated to increase the activity of the macrophages in a mammal suffering a disease.

37. A composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for administration to a mammal for decreasing the side effects of administering a non-steroidal anti-inflammatory agent, an effective amount of a non-steroidal anti-inflammatory agent (NSAID) for treating the patient and an amount of in excess of 200 mg/70 kg person of component (2) to facilitate the transport of the agent at the site to be treated through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated to decrease the side effects of the non-steroidal anti-inflammatory agent.

38. A composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for use to treat bone pain, muscle pain and/or inflammation, an

**SUBSTITUTE SHEET**

effective amount of Ascorbic Acid (Vitamin C) and an amount of component (2) to facilitate the transport of the agent at the site to be treated through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated.

39. A composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for enhancing prostaglandin synthesis inhibition, a therapeutically effective amount of a non-steroidal anti-inflammatory drug (NSAID) and an amount of component (2) to facilitate the transport of the agent at the site to be treated through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated.

40. A composition of Claim 1, 2, 3, 4, 5, 6, 7 or 8 comprising in a form adapted for treating a person with cancer, a therapeutically effective amount of a non-steroidal anti-inflammatory drug, and an amount of component (2) to facilitate the transport of the agent to penetrate at a site to be treated through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated.

41. A composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted to treat a disease or condition, a therapeutically effective amount of a non-steroidal anti-inflammatory agent and Vitamin C and an amount of component (2) to facilitate the transport of the agents at the site to be treated through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated.

42. A composition of Claim 1, 2, 3, 4, 5, 6, 7, or 8 comprising in a form adapted for decreasing the side effects of administering a drug, an effective amount of the drug for treating a patient and an amount in excess of 200 mg/70

kg person of component (2) to facilitate the transport of the agent at the site to be treated through the tissue (including scar tissue) through the cell membranes into the individual cells to be treated to decrease the side effects of the drug.

43. The composition of Claim 42 wherein the drug is a non-steroidal anti-inflammatory drug.

44. The use of

(1) a medicinal and/or therapeutic agent

and (2) hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and subunits of hyaluronic acid,

in the manufacture of a pharmaceutical composition for treating a disease or condition in humans in a therapy wherein a therapeutically effective amount of said medicinal and/or therapeutic agent is administered to a human, together with the hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and subunits of hyaluronic acid, the use being characterized in that the amount of component (2) is greater than 10 mg/70 kg person to facilitate the transport of component (1) through the tissue (including scar tissue) at the site to be treated through the cell membranes into the individual cells to be treated.

45. The use of Claim 44 wherein component (2) is hyaluronic acid and/or salts thereof.

46. The use according to Claim 44 or Claim 45 in a liquid form immediately available for penetration at a site to be treated.

**SUBSTITUTE SHEET**

- 11 -

47. The use of Claim 44, 45, or 46, wherein component (2) is utilized at a dose between 10 mg to 1000 mg/70 kg person.

48. The use of Claim 44, 45, or 46, wherein component (2) is utilized at a dose greater than 50 mg/70 kg person.

49. The use of Claim 44, 45, 46, 47, or 48, wherein component (2) is utilized at a dose between 50 mg and 1000 mg/70 kg person.

50. The use of Claim 44, 45, 46, or 48, wherein component (2) is utilized at a dose greater than 200 mg/70 kg person.

51. The use of Claim 44, 45, 46, 47, 48, 49, or 50, wherein component (1) comprises an agent selected from a free radical scavenger, ascorbic acid, Vitamin C, an anti-cancer agent, a chemotherapeutic agent, anti-viral agents, non-steroidal anti-inflammatory drugs (NSAID), steroidal anti-inflammatory drugs, an anti-fungal agent, detoxifying agents, analgesic, a bronchodilator, an anti-bacterial agent, antibiotics, drugs for the treatment of vascular ischemia, an antibody monoclonal agent, diuretics, immunosuppressants, lymphokynes, alpha-and- $\beta$ -interferon, insulin, estrogen, progestegen, anti-metabolites, calcium channel blockers, drugs for the treatment of psoriasis, an anti-cholinergic drug, histamine, H2 receptor antagonist, and combinations thereof.

52. The use of Claim 50 wherein component (1) is a non-steroidal anti-inflammatory drug (NSAID).

53. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said pharmaceutical composition is for the treatment of psoriasis and component (1) comprises a therapeutically effective amount of methotrexate.

**SUBSTITUTE SHEET**



- 12 -

54. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein component (1) comprises a cytotoxic chemotherapeutic agent selected from adriamycin, methotrexate, mitomycin C, bleomycin, 5-fluorouracil, novantrone, carbo and cis platinum, and combinations thereof.

55. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein component (1) is selected from phloridzin, phloretin, and 5-deoxyglucuronide of phloridzin, and combinations to competitively block glucose transport in neoplastic cells, and an agent selected from Vitamin C and a non-steroidal anti-inflammatory drug and combinations thereof.

56. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein component (1) comprises a diuretic.

57. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for the treatment of infection, and component (1) is selected from an antibiotic and antibacterial agent.

58. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for internal treatment, and component (1) comprises a non-steroidal anti-inflammatory agent and component (2) is hyaluronic acid and/or salts thereof.

59. The use of Claim 58 wherein the amount of hyaluronic acid and/or salts thereof exceeds 50 mg/70 kg person.

60. The use of Claim 58 wherein the amount of hyaluronic acid and/or salts thereof is present in an amount between 50 mg and 1000 mg/70 kg person.

SUBSTITUTE SHEET



- 14 -

68. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for the treatment of renal failure, cardiac insufficiency, hypertension, and edema, and component (1) comprises a diuretic.
69. The use of Claim 68 wherein the diuretic is furosemide.
70. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for the treatment of infection, and component (1) is selected from antibiotics, antibacterials, antimicrobials, and combinations thereof, with or without ascorbic acid.
71. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for the treatment of inflammation, and component (1) comprises a non-steroidal anti-inflammatory drug (NSAID).
72. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for assisting in the elimination of tumour breakdown material (including toxins, residue, and debris) in a person suffering from tumours, and component (1) comprises a non-steroidal anti-inflammatory drug (NSAID).
73. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for detoxifying a patient of toxins and component (1) comprises a detoxifying agent.
74. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for the treatment of infections surrounding implants in a patient, and component (1) comprises an antibiotic for treating the infected tissue surrounding the implant.

**SUBSTITUTE SHEET**

- 15 -

75. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for the treatment of a patient suffering from cancer and component (1) is selected from a non-steroidal anti-inflammatory agent, an anti-cancer agent, and combinations thereof.
76. The use of Claim 75 further comprising a therapeutically effective amount of ascorbic acid (Vitamin C).
77. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for the treatment of pain, and component (1) is a non-steroidal anti-inflammatory agent.
78. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is to provide enhanced neoplastic activity and effect and component (1) comprises ascorbic acid.
79. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for increasing the activity of the macrophages in mammals suffering from a disease, and component (1) comprises a non-steroidal anti-inflammatory agent.
80. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for decreasing the side effects of administering a non-steroidal anti-inflammatory drug, and component (1) is selected from a non-steroidal anti-inflammatory drug, and component (2) is present in an amount in excess of 200 mg/70 kg person.

SUBSTITUTE SHEET

- 16 -

81. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for the treatment of bone pain, muscle pain, and/or inflammation, and component (1) comprises ascorbic acid (Vitamin C).
82. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for enhancing prostaglandin synthesis inhibition, and component (1) comprises a non-steroidal anti-inflammatory drug (NSAID).
83. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for the treatment of cancer, and component (1) comprises a non-steroidal anti-inflammatory drug (NSAID).
84. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for the treatment of a disease or condition, and component (1) comprises a non-steroidal anti-inflammatory agent and Vitamin C.
85. The use of Claim 44, 45, 46, 47, 48, 49, 50, or 51, wherein said composition is for decreasing the side effects of a drug and component (2) is present in excess of 200 mg/70 kg person.
86. The use of Claim 85, wherein the drug comprises a non-steroidal anti-inflammatory drug.

**SUBSTITUTE SHEET**

These Notes are intended to facilitate the use of the present form. For full information see the text of the Patent Cooperation Treaty and the texts of the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and the said texts, the latter are applicable. „Article“ refers to Articles of the Treaty, „Rule“ refers to Rules of the Regulations and „Section“ refers to Sections of the Administrative Instructions.

(1) „If the claims have been amended, the report shall issue on the claims as amended.“ (Rule 70.2(a))

If the International Preliminary Examining Authority considers that any amendment goes beyond the disclosure in the international application as filed, the report shall be established as if such amendment had not been made, and the report shall so indicate. It shall also indicate the reasons why it considers that the amendment goes beyond the said disclosure.“ (Rule 70.2(c))

„If, before the International Preliminary Examining Authority, amendments have been made, this fact shall be indicated in the report. Where any amendments has resulted in the cancellation of an entire sheet, this fact shall also be specified in the report.“ (Rule 70.11)

„If the claims, the description, or the drawings, were amended before the International Preliminary Examining Authority, each replacement sheet under Rule 66.8(a) shall be annexed to the report. Replacement sheets superseded by later replacement sheets and letters under Rule 66.8(a) shall not be annexed.“ (Rule 70.16)

(2) „If pursuant to Rule 66.7(a) or (b), the report is established as if the priority had not been claimed, the report shall so indicate.“ (Rule 70.2(b))

„If the International Preliminary Examining Authority needs a copy of the application whose priority is claimed in the international application, the International Bureau shall, on request, promptly furnish such copy. If that copy is not furnished to the International Preliminary Examining Authority because the applicant failed to comply with the requirements of Rule 17.1, the international preliminary examination report may be established as if the priority had not been claimed.“ (Rule 66.7(a))

„If the application whose priority is claimed in the international application is in a language other than the language or one of the languages of the International Preliminary Examining Authority, that Authority may invite the applicant to furnish a translation in the said language or one of the said languages within 2 months from the date of the invitation. If the translation is not furnished within that time limit, the international preliminary examination report may be established as if the priority had not been claimed.“ (Rule 66.7(b))

See also Rule 70.10 in note 10 below.

(3) „If the applicant paid additional fees for the international preliminary examination, or if the international application or the international preliminary examination was restricted under Article 34(3), the report shall so indicate. Furthermore, where the international preliminary examination was carried out on restricted claims (Article 34(3)(a)), or on the main invention only (Article 34(3)(c)), the report shall indicate what parts of the international application were and what parts were not the subject of international preliminary examination.“ (Rule 70.13)

Rule 66 entitled „Lack of Unity of Invention (International Preliminary Examination)“ reads as follows:

#### „68.1 No Invitation to Restrict of Pay

Where the International Preliminary Examining Authority finds that the requirement of unity of invention is not complied with and chooses not to invite the applicant to restrict the claims or to pay additional fees, it shall establish the international preliminary examination report, subject to Article 34(4)(b), in respect of the entire international application, but shall indicate, in the said report, that, in its opinion, the requirement of unity of invention is not fulfilled and shall specify the reasons for which the international application is not considered as complying with the requirement of unity of invention.“

#### „68.2 Invitation to Restrict of Pay

Where the International Preliminary Examining Authority finds that the requirement of unity of invention is not complied with and chooses to invite the applicant, at his option, to restrict the claims or to pay additional fees, it shall specify at least one possibility of restriction which, in the opinion of the International Preliminary Examining Authority, would be in compliance with the applicable requirement, and shall specify the amount of the additional fees and the reasons for which the international application is not considered as complying with the requirement of unity of invention. It shall, at the same time, fix a time limit, with regard to the circumstances of the case, for complying with the invitation; such time limit shall not be shorter than 1 month, and it shall not be longer than 2 months, from the date of the invitation.“

#### „68.3 Additional Fees

(a) The amount of the additional fee due for international preliminary examination under Article 34(3)(a) shall be determined by the competent International Preliminary Examining Authority.

(b) The additional fee due to international preliminary examination under Article 34(3)(a) shall be payable direct to the International Preliminary Examining Authority.

(c) Any applicant may pay the additional fee under protest, that is, accompanied by a reasoned statement to the effect that the international application complies with the requirement of unity of invention or that the amount of the required additional fee is excessive. Such protest shall be examined by a three-member board or other special instance of the International Preliminary Examining Authority, or any competent higher authority, which, to the extent that it finds the protest justified, shall order the total or partial reimbursement to the applicant of the additional fee. On the request of the applicant, the text of both the protest and the decision thereon shall be notified to the elected Offices as an annex to the international preliminary examination report.

(d) The three-member board, special instance of competent higher authority, referred to in paragraph (c), shall not comprise any person who made the decision which is the subject of the protest.“

#### „68.4 Procedure in the Case of Insufficient Restriction of the Claims

If the applicant restricts the claims but not sufficiently to comply with the requirement of unity of invention, the International Preliminary Examining Authority shall proceed as provided in Article 34(3)(c).“

#### „68.5 Main Invention

In case of doubt which invention is the main invention for the purposes of Article 34(3)(c), the invention first mentioned in the claims shall be considered the main invention.“

(4) „If the International Preliminary Examining Authority considers

(i) that the international application relates to a subject matter on which the International Preliminary Examining Authority is not required, under the Regulations, to carry out an international preliminary examination, and in the particular case decides not to carry out such examination, or

(ii) that the description, the claims, or the drawings are so unclear that the claims are so inadequately supported by the description, that no meaningful opinion can be formed on the novelty, inventive step (non-obviousness), or industrial applicability, of the claimed invention,

the said Authority shall not go into the questions referred to in Article 33(ii) and shall inform the applicant of his opinion and the reasons therefor.“ (Article 34(4)(a))

„If any of the situations referred to in subparagraph (a) is found to exist in, or in connection with, certain claims only, the provisions of that subparagraph shall apply only to the said claims.“ (Article 34(4)(b))

„If, at the time of establishing the international preliminary examination report, the International Preliminary Examining Authority considers that any of the situations referred to in Article 34(4)(a) exists, that report shall state this opinion and the reasons therefor...“ (Article 35(3)(a))

„If a situation under Article 34(4)(b) is found to exist, the international preliminary examination report shall, in relation to the claims in question, contain the statement as provided in subparagraph (a)...“ (Article 35(3)(b))

„Where the national law of the national Office acting as International Preliminary Examining Authority does not allow multiple dependent claims to be drafted in a manner different from that provided for in the second and third sentences of Rule 6.4 the International Preliminary Examining Authority may in case of failure to use that manner of claiming, apply Article 34(4)(b)...“ (Rule 66.2(a))

Rule 67 entitled „Subject Matter under Article 34(4)(a)(i)“ reads as follows:

#### „67.1 Definition

No International Preliminary Examining Authority shall be required to carry out an international preliminary examination on an international application, if and to the extent to which, its subject matter is any of the following:

- (i) scientific and mathematical theories,
- (ii) plant or animal varieties or essentially biological processes for the production of plants and animals, other than microbiological processes and the products of such processes,
- (iii) schemes, rules or methods of doing business, performing purely mental acts or playing games,
- (iv) methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods,
- (v) mere presentations of information,
- (vi) computer programs to the extent that the International Preliminary Examining Authority is not equipped to carry out an international preliminary examination concerning such programs.“

(5) „The report shall repeat the classification given under Rule 43.3 [classification of the subject matter in the international search report] if the International Preliminary Examining Authority agrees with such classification.“ (Rule 70.5(a))

„Otherwise, the International Preliminary Examining Authority shall indicate in the report the classification, at least according to the International Patent Classification, which it considers correct.“ (Rule 70.5(b))

(6) „The international preliminary examination report shall contain any statement on the question whether the claimed invention is ~~to~~ seems to be patentable or unpatentable according to any national law. It shall state, subject to the provisions of paragraph (3), in relation to each claim, whether the claim appears to satisfy the criteria of novelty, inventive step (non-obviousness), and industrial applicability, as defined for the purposes of the international preliminary examination in Article 33(1) to (4). The statement shall be accompanied by the citation of the documents believed to support the stated conclusion with such explanations as the circumstances of the case may require. The statement shall also be accompanied by such other observations as the Regulations provide for.” **(Article 35(2))**  
 „The statement referred to in Article 35(2) shall consist of the words „YES” or „NO”, or their equivalent in the language of the report, or some appropriate sign provided for in the Administrative Instructions, and shall be accompanied by the citations, explanations and observations, if any, referred to in the last sentence of Article 35(2).” **(Rule 70.6(a))**  
 „If any of the three criteria referred to in Article 35(2) (that is, novelty, inventive step (non-obviousness), industrial applicability) is not satisfied, the statement shall be negative. If, in such a case, any of the criteria taken separately, is satisfied, the report shall specify the criterion or criteria so satisfied.” **(Rule 70.6(b))**

7. See **Article 35(2)** in the preceding note.

„The report shall cite the documents considered to be relevant for supporting the statements made under Article 35(2).” **(Rule 70.7(a))**

„The provisions of Rule 43.5(b) and (e) shall apply also the report.” **(Rule 70.7(b))**

„The method of identifying any cited documents shall be regulated by the Administrative Instructions.” **(Rule 43.5(b))**

„If only certain passages of the cited document are relevant or particularly relevant, they shall be identified, for example, by indicating the page, the column, or the lines, where the passage appears.” **(Rule 43.5(e))**

„Identification of any document cited in the international search report referred to in Rule 43.5(b) shall be made by indicating the following elements in the order in which they are listed:

- (a) **In the case of any patent document** (patent documents being patents within the meaning of Article 2(ii) as well as published applications relating thereto):
  - (i) the Office that issued the document, by the two-letter code as in Annex B;
  - (ii) the kind of document, by the appropriate symbols as in the Standard Code for Identification of Different Kinds of Patent Documents (ST.16);
  - (iii) the number of document as given to it by the Office that issued it (for Japanese patent documents the indication of the year of the reign of the Emperor must precede the serial number of the patent document);
  - (iv) the name of the patentee of applicant (in capital letters, where appropriate abbreviated);
  - (v) the date of publication of the cited patent document as indicated thereon; and
  - (vi) where applicable, the pages, columns or lines where the relevant passages appear, or the relevant figures of the drawings.

(The following example illustrates the citation of a patent according to paragraph (a) above:  
 JP. B. 50-14535 (NCR CORPORATION) 28 May 1975 (28.05.75), see column 4, lines 3 to 27.)

(b) **In the case of any book or other separately issued publication:**

- (i) the name of the author;
- (ii) the title (including, where applicable, the number of the edition and/or volume);
- (iii) the year of publication (when this coincides with the year of the international application or of the priority claim, the International Search Authority shall endeavour to determine the month and, if necessary, the day of publication and to indicate these data in the international search report);
- (iv) the name of the publisher;
- (v) as far as available, the place of publication (where only the location of the publisher appears on the book or other separately issued publication, then that location shall be indicated as the place of publication); and
- (vi) where applicable the pages, columns or lines where the relevant passages appear, or the relevant figures of the drawings.

(The following example illustrates the citation of a book or other separately issued publication according to paragraph (b) above:  
 H. Walton, 'Microwave Quantum Theory', Volume 2, published 1973, by Sweet and Maxwell (London), see pages 138 to 192, especially pages 146 to 148.)

(c) **In the case of any article published in a periodical or other serial publication:**

- (i) the title of the periodical or other serial publication;
- (ii) the number of the volume and the date of the issue in which the article appears;
- (iii) as far as available, the place of publication (where only the location of the publisher appears in the periodical or other serial publication, then that location shall be indicated as the place of publication);
- (iv) the author and the title of the article and the number of the page both on which the article starts and ends; and

(v) where applicable, the pages, columns or lines where the relevant passages appear, or the relevant figures of the drawings.

(The following example illustrates the citation of an article published in a periodical or other serial publication according to paragraph (c) above:  
 IBM Technical Disclosure Bulletin, Volume 17, no. 5, issued 1974 October (Armonk, New York) J.G. Drop, 'Integrated Circuit Personalization at the Module Level', see pages 1344 to 1345.)

(d) **In the case of abstracts**

- (i) the identification of the document containing the abstract in the manner set forth in paragraphs (a), (b) and (c), respectively, depending upon whether the abstract is contained in a patent document, in a book or other separately issued publication, or in an article published in a periodical or other serial publication;
- (ii) in the case where the abstract is not published together with the full text document which served as its basis, the identification of both abstract and full text document on the basis of whatever bibliographic data may be available in respect thereto.”

(The following example illustrates the citation of an abstract according to paragraph (d)(ii) above:

Chemical Abstracts, Volume 75, no.20, issued 1971, November 15 (Columbus, Ohio, U.S.A.), D.I. Shetulov, 'Surface Effects During Metal Fatigue', see page 163, column 1, the abstract no. 120718k, Fiz.-Khim. Mekh. Mater. 1971, 7(2), 7-11 (Russ.).” (Section 503)

(8) See **Article 35(2)** in note 10 above.

„The Administrative Instructions shall contain guidelines for cases in which the explanations referred to in Article 35(2) should or should not be given and the form of such explanations. Such guidelines shall be based on the following principles:

- (i) explanations shall be given whenever the statement in relation to any claim is negative;
- (ii) explanations shall be given whenever the statement is positive unless the reason for citing any document is easy to imagine on the basis of consultation of the cited document;
- (iii) generally, explanations shall be given if the case provided for in the last sentence of Rule 70.6(b) obtains.” **(Rule 70.8)**

„Explanations under Rule 70.8 shall clearly point out to which of the three criteria referred to in Article 35(2), taken separately, any cited document is applicable and shall clearly describe, with reference to the cited documents, the reasons supporting the conclusion that any of the said criteria is or is not satisfied.” **(Section 604)**

9. „Any non-written disclosure referred to in the report by virtue of Rule 64.2 shall be mentioned by indicating its kind, the date on which the written disclosure referring to the non-written disclosure was made available to the public, and the date on which the non-written disclosure occurred in public.”

**(Rule 70.9)**  
 „In cases where the making available to the public occurred by means of an oral disclosure, use, exhibition or other non-written means („non-written disclosure”) before the relevant date as defined in Rule 64.1(b) and the date of such non-written disclosure is indicated in a written disclosure which has been made available to the public after the relevant date, the non-written disclosure shall not be considered part of the prior art for the purposes of Article 33(2) and (3). Nevertheless, the international preliminary examination report shall call attention to such non-written disclosure in the manner provided for in Rule 70.9.” **(Rule 64.2)**

(10) „Any published application or any patent referred to in the report by virtue of Rule 64.3 shall be mentioned as such and shall be accompanied by an indication of its date of publication, of its filing date, and its claimed priority date (if any). In respect of the priority date of any such document, the report may indicate that, in the opinion of the International Preliminary Examining Authority, such date has not been validly claimed.” **(Rule 70.10)**

„In cases where any application or any patent which would constitute prior art for the purposes of Article 33(2) and (3) had it been published prior to the relevant date referred to in Rule 64.1 was published, as such, after the relevant date but was filed earlier than the relevant date or claimed the priority of an earlier application which had been filed prior to the relevant date, such published application or patent shall not be considered part of the prior art for the purposes of Article 33(2) and (3). Nevertheless, the international preliminary examination report shall call attention to such application or patent in the manner provided for in Rule 70.10.” **(Rule 64.3)**

(11) „If the International Preliminary Examining Authority considers that, at the time it prepares the report:

- (i) the international application contains any of the defects referred to in Rule 66.2(a)(iii) (defect in the form or contents of the international application under the Treaty or the Regulations thereunder), it shall include this opinion and the reasons therefor in the report;
- (ii) the international application calls for any of the observations referred to in Rule 66.2(a)(v) (observations on the clarity of the claims, the description, and the drawings or the question whether the claims are fully supported by the description), it may include this opinion in the report and if it does, it shall also indicate in the report the reasons for such opinion.” **(Rule 70.12)**

(12) See **Rule 70.12(ii)** in the preceding note.

These Notes are intended to facilitate the use of the present form. For full information see the text of the Patent Cooperation Treaty and the texts of the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and the said texts, the latter are applicable. „Article“ refers to Articles of the Treaty, „Rule“ refers to Rules of the Regulations and „Section“ refers to Sections of the Administrative Instructions.

(1) „If the claims have been amended, the report shall issue on the claims as amended.“ (Rule 70.2(a))

If the International Preliminary Examining Authority considers that any amendment goes beyond the disclosure in the international application as filed, the report shall be established as if such amendment had not been made, and the report shall so indicate. It shall also indicate the reasons why it considers that the amendment goes beyond the said disclosure.“ (Rule 70.2(c))

„If, before the International Preliminary Examining Authority, amendments have been made, this fact shall be indicated in the report. Where any amendments has resulted in the cancellation of an entire sheet, this fact shall also be specified in the report.“ (Rule 70.11)

„If the claims, the description, or the drawings, were amended before the International Preliminary Examining Authority, each replacement sheet under Rule 66.8(a) shall be annexed to the report. Replacement sheets superseded by later replacement sheets and letters under Rule 66.8(a) shall not be annexed.“ (Rule 70.16)

(2) „If pursuant to Rule 66.7(a) or (b), the report is established as if the priority had not been claimed, the report shall so indicate.“ (Rule 70.2(b))

„If the International Preliminary Examining Authority needs a copy of the application whose priority is claimed in the international application, the International Bureau shall, on request, promptly furnish such copy. If that copy is not furnished to the International Preliminary Examining Authority because the applicant failed to comply with the requirements of Rule 17.1, the international preliminary examination report may be established as if the priority had not been claimed.“ (Rule 66.7(a))

„If the application whose priority is claimed in the international application is in a language other than the language or one of the languages of the International Preliminary Examining Authority, that Authority may invite the applicant to furnish a translation in the said language or one of the said languages within 2 months from the date of the invitation. If the translation is not furnished within that time limit, the international preliminary examination report may be established as if the priority had not been claimed.“ (Rule 66.7(b))

See also Rule 70.10 in note 10 below.

(3) „If the applicant paid additional fees for the international preliminary examination, or if the international application or the international preliminary examination was restricted under Article 34(3), the report shall so indicate. Furthermore, where the international preliminary examination was carried out on restricted claims (Article 34(3)(a)), or on the main invention only (Article 34(3)(c)), the report shall indicate what parts of the international application were and what parts were not the subject of international preliminary examination.“ (Rule 70.13)

Rule 68 entitled „Lack of Unity of Invention (International Preliminary Examination)“ reads as follows:

#### „68.1 No Invitation to Restrict of Pay

Where the International Preliminary Examining Authority finds that the requirement of unity of invention is not complied with and chooses not to invite the applicant to restrict the claims or to pay additional fees, it shall establish the international preliminary examination report, subject to Article 34(4)(b), in respect of the entire international application, but shall indicate, in the said report, that, in its opinion, the requirement of unity of invention is not fulfilled and shall specify the reasons for which the international application is not considered as complying with the requirement of unity of invention.“

#### „68.2 Invitation to Restrict of Pay

Where the International Preliminary Examining Authority finds that the requirement of unity of invention is not complied with and chooses to invite the applicant, at his option, to restrict the claims or to pay additional fees, it shall specify at least one possibility of restriction which, in the opinion of the International Preliminary Examining Authority, would be in compliance with the applicable requirement, and shall specify the amount of the additional fees and the reasons for which the international application is not considered as complying with the requirement of unity of invention. It shall, at the same time, fix a time limit, with regard to the circumstances of the case, for complying with the invitation; such time limit shall not be shorter than 1 month, and it shall not be longer than 2 months, from the date of the invitation.“

#### „68.3 Additional Fees

(a) The amount of the additional fee due for international preliminary examination under Article 34(3)(a) shall be determined by the competent International Preliminary Examining Authority.

(b) The additional fee due to international preliminary examination under Article 34(3)(a) shall be payable direct to the International Preliminary Examining Authority.

(c) Any applicant may pay the additional fee under protest, that is, accompanied by a reasoned statement to the effect that the international application complies with the requirement of unity of invention or that the amount of the required additional fee is excessive. Such protest shall be examined by a three-member board or other special instance of the International Preliminary Examining Authority, or any competent higher authority, which, to the extent that it finds the protest justified, shall order the total or partial reimbursement to the applicant of the additional fee. On the request of the applicant, the text of both the protest and the decision thereon shall be notified to the elected Offices as an annex to the international preliminary examination report.

(d) The three-member board, special instance of competent higher authority, referred to in paragraph (c), shall not comprise any person who made the decision which is the subject of the protest.“

#### „68.4 Procedure in the Case of Insufficient Restriction of the Claims

If the applicant restricts the claims but not sufficiently to comply with the requirement of unity of invention, the International Preliminary Examining Authority shall proceed as provided in Article 34(3)(c).“

#### „68.5 Main Invention

In case of doubt which invention is the main invention for the purposes of Article 34(3)(c), the invention first mentioned in the claims shall be considered the main invention.“

(4) „If the International Preliminary Examining Authority considers

(i) that the international application relates to a subject matter on which the International Preliminary Examining Authority is not required, under the Regulations, to carry out an international preliminary examination, and in the particular case decides not to carry out such examination, or

(ii) that the description, the claims, or the drawings are so unclear that the claims are so inadequately supported by the description, that no meaningful opinion can be formed on the novelty, inventive step (non-obviousness), or industrial applicability, of the claimed invention, the said Authority shall not go into the questions referred to in Article 33(ii) and shall inform the applicant of his opinion and the reasons therefor.“

(Article 34(4)(a))

„If any of the situations referred to in subparagraph (a) is found to exist in, or in connection with, certain claims only, the provisions of that subparagraph shall apply only to the said claims.“ (Article 34(4)(b))

„If, at the time of establishing the international preliminary examination report, the International Preliminary Examining Authority considers that any of the situations referred to in Article 34(4)(a) exists, that report shall state this opinion and the reasons therefor.“ (Article 35(3)(a))

„If a situation under Article 34(4)(b) is found to exist, the international preliminary examination report shall, in relation to the claims in question, contain the statement as provided in subparagraph (a), ...“ (Article 35(3)(b))

„...Where the national law of the national Office acting as International Preliminary Examining Authority does not allow multiple dependent claims to be drafted in a manner different from that provided for in the second and third sentences of Rule 6.4 the International Preliminary Examining Authority may in case of failure to use that manner of claiming, apply Article 34(4)(b) ...“ (Rule 66.2(a))

Rule 67 entitled „Subject Matter under Article 34(4)(a)(i)“ reads as follows:

#### „67.1 Definition

No International Preliminary Examining Authority shall be required to carry out an international preliminary examination on an international application, if and to the extent to which, its subject matter is any of the following:

- (i) scientific and mathematical theories,
- (ii) plant or animal varieties or essentially biological processes for the production of plants and animals, other than microbiological processes and the products of such processes,
- (iii) schemes, rules or methods of doing business, performing purely mental acts or playing games,
- (iv) methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods,
- (v) mere presentations of information,
- (vi) computer programs to the extent that the International Preliminary Examining Authority is not equipped to carry out an international preliminary examination concerning such programs.“

(5) „The report shall repeat the classification given under Rule 43.3 [classification of the subject matter in the international search report] if the International Preliminary Examining Authority agrees with such classification.“ (Rule 70.5(a))

„Otherwise, the International Preliminary Examining Authority shall indicate in the report the classification, at least according to the International Patent Classification, which it considers correct.“ (Rule 70.5(b))